US20020161001A1 - Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV - Google Patents
Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV Download PDFInfo
- Publication number
- US20020161001A1 US20020161001A1 US09/935,149 US93514901A US2002161001A1 US 20020161001 A1 US20020161001 A1 US 20020161001A1 US 93514901 A US93514901 A US 93514901A US 2002161001 A1 US2002161001 A1 US 2002161001A1
- Authority
- US
- United States
- Prior art keywords
- dione
- alkyl
- benzyl
- purine
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VLNITFWQYJADSY-UHFFFAOYSA-N CC.CCC(C)(C)N1C(N2CCNC2)=NC2=C1C(=O)N(C)C(=O)N2C Chemical compound CC.CCC(C)(C)N1C(N2CCNC2)=NC2=C1C(=O)N(C)C(=O)N2C VLNITFWQYJADSY-UHFFFAOYSA-N 0.000 description 7
- 0 CN(CCN*)c1nc(N(*)C(N(*)C2=O)=O)c2[n]1C(*)(*)** Chemical compound CN(CCN*)c1nc(N(*)C(N(*)C2=O)=O)c2[n]1C(*)(*)** 0.000 description 7
- YPBLCMLMLKMJGR-UHFFFAOYSA-N CCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C1=O Chemical compound CCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C1=O YPBLCMLMLKMJGR-UHFFFAOYSA-N 0.000 description 3
- PJVHDXULZUFZSK-UHFFFAOYSA-N C1=CC=C(CC2=CC=CC=C2N2CCNCC2)C=C1 Chemical compound C1=CC=C(CC2=CC=CC=C2N2CCNCC2)C=C1 PJVHDXULZUFZSK-UHFFFAOYSA-N 0.000 description 2
- JQQVFOBGUYOMQP-UHFFFAOYSA-N CC(C)C1=C(N2CCNCC2)C=CC=C1 Chemical compound CC(C)C1=C(N2CCNCC2)C=CC=C1 JQQVFOBGUYOMQP-UHFFFAOYSA-N 0.000 description 2
- HSKZVLCVTRGJNI-UHFFFAOYSA-N CC(C)CCCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CC(C)CCCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(C)C1=O HSKZVLCVTRGJNI-UHFFFAOYSA-N 0.000 description 2
- DDOXTTNJPLMGEL-UHFFFAOYSA-N CC(C)CCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CC(C)CCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(C)C1=O DDOXTTNJPLMGEL-UHFFFAOYSA-N 0.000 description 2
- IEFOAQSPBNGTIC-UHFFFAOYSA-N CC1=C(C)C2=NN=NN2C1 Chemical compound CC1=C(C)C2=NN=NN2C1 IEFOAQSPBNGTIC-UHFFFAOYSA-N 0.000 description 2
- RPWLPIKIULUGGV-UHFFFAOYSA-N CC1=C2NC=NC2=CC=C1N Chemical compound CC1=C2NC=NC2=CC=C1N RPWLPIKIULUGGV-UHFFFAOYSA-N 0.000 description 2
- NATXVTGOBMUXMM-UHFFFAOYSA-N CC1=CC=C2C=CNC2=C1C Chemical compound CC1=CC=C2C=CNC2=C1C NATXVTGOBMUXMM-UHFFFAOYSA-N 0.000 description 2
- DWIWTQLAKTVXBM-UHFFFAOYSA-N CC1=NC(CN2C(N3CCCNCC3)=NC3=C2C(=O)NC(=O)N3C)=CS1 Chemical compound CC1=NC(CN2C(N3CCCNCC3)=NC3=C2C(=O)NC(=O)N3C)=CS1 DWIWTQLAKTVXBM-UHFFFAOYSA-N 0.000 description 2
- LPBBSTYIOVFJOE-UHFFFAOYSA-N CC1CN2C=CC=C2C1C Chemical compound CC1CN2C=CC=C2C1C LPBBSTYIOVFJOE-UHFFFAOYSA-N 0.000 description 2
- XJZVCNGBKRTGFO-UHFFFAOYSA-N CCCCC1=CC=CC=C1N1CCNCC1 Chemical compound CCCCC1=CC=CC=C1N1CCNCC1 XJZVCNGBKRTGFO-UHFFFAOYSA-N 0.000 description 2
- TZRONFORCHMLNM-UHFFFAOYSA-N CCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(C)C1=O TZRONFORCHMLNM-UHFFFAOYSA-N 0.000 description 2
- XDHIOZBDJAHMKX-UHFFFAOYSA-N CCCN1C2=CC=CC=C2N=C1N1CCNCC1 Chemical compound CCCN1C2=CC=CC=C2N=C1N1CCNCC1 XDHIOZBDJAHMKX-UHFFFAOYSA-N 0.000 description 2
- XNXZBRXFGVBSCN-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CC4CC3CN4)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CC4CC3CN4)N2CC2=CC=CC=C2)N(C)C1=O XNXZBRXFGVBSCN-UHFFFAOYSA-N 0.000 description 2
- QGBNTEXAVHATFK-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC(=O)N2CCCC2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC(=O)N2CCCC2)N(C)C1=O QGBNTEXAVHATFK-UHFFFAOYSA-N 0.000 description 2
- GWGJFRLRJPHMSY-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2F)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2F)N(C)C1=O GWGJFRLRJPHMSY-UHFFFAOYSA-N 0.000 description 2
- ULAHPACZETZFAE-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC(C#N)=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC(C#N)=C2)N(C)C1=O ULAHPACZETZFAE-UHFFFAOYSA-N 0.000 description 2
- OQTJURQATCCKKL-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2I)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2I)N(C)C1=O OQTJURQATCCKKL-UHFFFAOYSA-N 0.000 description 2
- MVRUYOHKQDONBC-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CCCC#N)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CCCC#N)N(C)C1=O MVRUYOHKQDONBC-UHFFFAOYSA-N 0.000 description 2
- UBJCRIOBVOIOBF-RIYZIHGNSA-N CN1C(=O)N(C/C=C/C2=CC=CC=C2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 Chemical compound CN1C(=O)N(C/C=C/C2=CC=CC=C2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 UBJCRIOBVOIOBF-RIYZIHGNSA-N 0.000 description 2
- DEXALYHNKOPCGP-UHFFFAOYSA-N CN1C(=O)N(CC2CCCCO2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CC2CCCCO2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 DEXALYHNKOPCGP-UHFFFAOYSA-N 0.000 description 2
- XOBBNSWCWZBJEQ-UHFFFAOYSA-N CN1C(=O)N(CC2OCCO2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CC2OCCO2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 XOBBNSWCWZBJEQ-UHFFFAOYSA-N 0.000 description 2
- TXBOFWTZGOSLJG-UHFFFAOYSA-N CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 Chemical compound CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 TXBOFWTZGOSLJG-UHFFFAOYSA-N 0.000 description 2
- QGTFEGHGPMCJRF-UHFFFAOYSA-N CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1C1=CC=CC=C1 Chemical compound CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1C1=CC=CC=C1 QGTFEGHGPMCJRF-UHFFFAOYSA-N 0.000 description 2
- SVHOUFPLNDEKQV-UHFFFAOYSA-N CN1CC2CCCC2N1C Chemical compound CN1CC2CCCC2N1C SVHOUFPLNDEKQV-UHFFFAOYSA-N 0.000 description 2
- RPDICRQSEPSTAN-UHFFFAOYSA-N COC(=O)C1=CC=C(CN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)C(OC)=C1 Chemical compound COC(=O)C1=CC=C(CN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)C(OC)=C1 RPDICRQSEPSTAN-UHFFFAOYSA-N 0.000 description 2
- URZNPYLSKANYBX-UHFFFAOYSA-N COC1=CC(CN2C(=O)C3=C(N=C(N4CCNCC4)N3CC3=C(I)C=CC=C3)N(C)C2=O)=CC(OC)=C1 Chemical compound COC1=CC(CN2C(=O)C3=C(N=C(N4CCNCC4)N3CC3=C(I)C=CC=C3)N(C)C2=O)=CC(OC)=C1 URZNPYLSKANYBX-UHFFFAOYSA-N 0.000 description 2
- AALWPTUPHRGAQQ-UHFFFAOYSA-N COCCOCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O Chemical compound COCCOCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O AALWPTUPHRGAQQ-UHFFFAOYSA-N 0.000 description 2
- FRFKCMNQNNNZNO-UHFFFAOYSA-N FC(F)(F)C1=CC=CN=C1N1CCNCC1.[H]Cl Chemical compound FC(F)(F)C1=CC=CN=C1N1CCNCC1.[H]Cl FRFKCMNQNNNZNO-UHFFFAOYSA-N 0.000 description 2
- JGRYCVHBJUYLBF-UHFFFAOYSA-N O=C1NC(=O)N(CC2=CC=CC=C2)C2=C1N(CC1=CC=CC=C1)C(N1CCCNCC1)=N2 Chemical compound O=C1NC(=O)N(CC2=CC=CC=C2)C2=C1N(CC1=CC=CC=C1)C(N1CCCNCC1)=N2 JGRYCVHBJUYLBF-UHFFFAOYSA-N 0.000 description 2
- ASBVLJIRSGFRCR-AEJSXWLSSA-N [H][C@@]12C/C=C\[C@]1([H])C=C(C)[C@@H]2C Chemical compound [H][C@@]12C/C=C\[C@]1([H])C=C(C)[C@@H]2C ASBVLJIRSGFRCR-AEJSXWLSSA-N 0.000 description 2
- GOVOUBJGMRGCLX-BIIVOSGPSA-N [H][C@]12CCCN1O[C@@H](C)[C@@H]2C Chemical compound [H][C@]12CCCN1O[C@@H](C)[C@@H]2C GOVOUBJGMRGCLX-BIIVOSGPSA-N 0.000 description 2
- GOVOUBJGMRGCLX-BWZBUEFSSA-N [H][C@]12CCCN1O[C@H](C)[C@H]2C Chemical compound [H][C@]12CCCN1O[C@H](C)[C@H]2C GOVOUBJGMRGCLX-BWZBUEFSSA-N 0.000 description 2
- WOAURKKOLJHZGI-UHFFFAOYSA-N C/C1=C(\C)C2=CN=NN2C1 Chemical compound C/C1=C(\C)C2=CN=NN2C1 WOAURKKOLJHZGI-UHFFFAOYSA-N 0.000 description 1
- DUKJOKUHNADCBQ-UHFFFAOYSA-N C/C1=C2\C=CC=C2CCN1C Chemical compound C/C1=C2\C=CC=C2CCN1C DUKJOKUHNADCBQ-UHFFFAOYSA-N 0.000 description 1
- RELCQEGAWBQQLH-UHFFFAOYSA-N C1=CC=C(CC2=C(C3CCNCC3)C=CC=C2)C=C1 Chemical compound C1=CC=C(CC2=C(C3CCNCC3)C=CC=C2)C=C1 RELCQEGAWBQQLH-UHFFFAOYSA-N 0.000 description 1
- PWWDCRQZITYKDV-UHFFFAOYSA-N C1=CC=C(CN2C3=CC=CC=C3N=C2N2CCNCC2)C=C1 Chemical compound C1=CC=C(CN2C3=CC=CC=C3N=C2N2CCNCC2)C=C1 PWWDCRQZITYKDV-UHFFFAOYSA-N 0.000 description 1
- SHERAUCGTHRFCU-UHFFFAOYSA-N CC(=O)CN1C(N2CCNCC2)=NC2=C1C(=O)N(C)C(=O)N2C Chemical compound CC(=O)CN1C(N2CCNCC2)=NC2=C1C(=O)N(C)C(=O)N2C SHERAUCGTHRFCU-UHFFFAOYSA-N 0.000 description 1
- UHVOJZSCTIGFND-UHFFFAOYSA-N CC(C)(C)NC(=O)C1=CC=CN=C1N1CCNCC1 Chemical compound CC(C)(C)NC(=O)C1=CC=CN=C1N1CCNCC1 UHVOJZSCTIGFND-UHFFFAOYSA-N 0.000 description 1
- RRGCXOMYSQPOSN-UHFFFAOYSA-N CC(C)C1CN(C2=NC3=C(C(=O)N(C)C(=O)N3C)N2CC2=CC=CC=C2)CCN1 Chemical compound CC(C)C1CN(C2=NC3=C(C(=O)N(C)C(=O)N3C)N2CC2=CC=CC=C2)CCN1 RRGCXOMYSQPOSN-UHFFFAOYSA-N 0.000 description 1
- RRGCXOMYSQPOSN-INIZCTEOSA-N CC(C)[C@@H]1CN(C2=NC3=C(C(=O)N(C)C(=O)N3C)N2CC2=CC=CC=C2)CCN1 Chemical compound CC(C)[C@@H]1CN(C2=NC3=C(C(=O)N(C)C(=O)N3C)N2CC2=CC=CC=C2)CCN1 RRGCXOMYSQPOSN-INIZCTEOSA-N 0.000 description 1
- RRGCXOMYSQPOSN-MRXNPFEDSA-N CC(C)[C@H]1CN(C2=NC3=C(C(=O)N(C)C(=O)N3C)N2CC2=CC=CC=C2)CCN1 Chemical compound CC(C)[C@H]1CN(C2=NC3=C(C(=O)N(C)C(=O)N3C)N2CC2=CC=CC=C2)CCN1 RRGCXOMYSQPOSN-MRXNPFEDSA-N 0.000 description 1
- BEHAXAWRLPRXQA-UHFFFAOYSA-N CC(C1=CC=CC=C1)N1C(N2CCNCC2)=NC2=C1C(=O)N(C)C(=O)N2C Chemical compound CC(C1=CC=CC=C1)N1C(N2CCNCC2)=NC2=C1C(=O)N(C)C(=O)N2C BEHAXAWRLPRXQA-UHFFFAOYSA-N 0.000 description 1
- XQEGWGXBPPWQNU-UHFFFAOYSA-N CC(CO)CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O Chemical compound CC(CO)CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O XQEGWGXBPPWQNU-UHFFFAOYSA-N 0.000 description 1
- HVDNFWUPVJSVCF-UHFFFAOYSA-N CC(CO)CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O Chemical compound CC(CO)CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O HVDNFWUPVJSVCF-UHFFFAOYSA-N 0.000 description 1
- QYLRQRANYYXDSZ-UHFFFAOYSA-N CC(O)CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O Chemical compound CC(O)CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O QYLRQRANYYXDSZ-UHFFFAOYSA-N 0.000 description 1
- SITXHBOSNKIOHE-RCUQKECRSA-N CC.CC.II.[2HH].[H]N1CCC(C2CC3CCCC3C2C(C)(C)CC)C1 Chemical compound CC.CC.II.[2HH].[H]N1CCC(C2CC3CCCC3C2C(C)(C)CC)C1 SITXHBOSNKIOHE-RCUQKECRSA-N 0.000 description 1
- VNJXRHVMRBYMPR-UHFFFAOYSA-N CC1/C2=C/C=C\N2CCN1C Chemical compound CC1/C2=C/C=C\N2CCN1C VNJXRHVMRBYMPR-UHFFFAOYSA-N 0.000 description 1
- NHBDBOQDOZPMFZ-UHFFFAOYSA-N CC1=C(C)C2=C(C=C1)CCC2 Chemical compound CC1=C(C)C2=C(C=C1)CCC2 NHBDBOQDOZPMFZ-UHFFFAOYSA-N 0.000 description 1
- GRQDMLVPPFIGCI-UHFFFAOYSA-N CC1=C(C)C2=C(C=C1)NC=N2 Chemical compound CC1=C(C)C2=C(C=C1)NC=N2 GRQDMLVPPFIGCI-UHFFFAOYSA-N 0.000 description 1
- ZLMWTIIXMPCVIW-UHFFFAOYSA-N CC1=C(C)C2=C(C=C1)SC=C2 Chemical compound CC1=C(C)C2=C(C=C1)SC=C2 ZLMWTIIXMPCVIW-UHFFFAOYSA-N 0.000 description 1
- AOFNFTGRWHIIOL-UHFFFAOYSA-N CC1=C(C)C2=C(C=CS2)C=N1 Chemical compound CC1=C(C)C2=C(C=CS2)C=N1 AOFNFTGRWHIIOL-UHFFFAOYSA-N 0.000 description 1
- VUPOKHSAFAWAEH-UHFFFAOYSA-N CC1=C(C)C2=C(C=CS2)CC1 Chemical compound CC1=C(C)C2=C(C=CS2)CC1 VUPOKHSAFAWAEH-UHFFFAOYSA-N 0.000 description 1
- UVOACZBCXYHCJI-UHFFFAOYSA-N CC1=C(C)C2=C(C=N1)CCC2 Chemical compound CC1=C(C)C2=C(C=N1)CCC2 UVOACZBCXYHCJI-UHFFFAOYSA-N 0.000 description 1
- OUCJRYHGEVWFOA-UHFFFAOYSA-N CC1=C(C)C2=C(C=N1)SC=C2 Chemical compound CC1=C(C)C2=C(C=N1)SC=C2 OUCJRYHGEVWFOA-UHFFFAOYSA-N 0.000 description 1
- ZNSWPMYKGIIAHV-UHFFFAOYSA-N CC1=C(C)C2=C(CC1)SC=C2 Chemical compound CC1=C(C)C2=C(CC1)SC=C2 ZNSWPMYKGIIAHV-UHFFFAOYSA-N 0.000 description 1
- YTEIFKJRGDTWPB-UHFFFAOYSA-N CC1=C(C)C2=C(CCC2)N=N1 Chemical compound CC1=C(C)C2=C(CCC2)N=N1 YTEIFKJRGDTWPB-UHFFFAOYSA-N 0.000 description 1
- GWFAQTPMTQTAJA-UHFFFAOYSA-N CC1=C(C)C2=CCCC2=C1 Chemical compound CC1=C(C)C2=CCCC2=C1 GWFAQTPMTQTAJA-UHFFFAOYSA-N 0.000 description 1
- YLDQSMYZCNLSGN-UHFFFAOYSA-N CC1=C(C)C2=NN=CN2NC1 Chemical compound CC1=C(C)C2=NN=CN2NC1 YLDQSMYZCNLSGN-UHFFFAOYSA-N 0.000 description 1
- CFMFOFBPGJOQSR-UHFFFAOYSA-N CC1=C(C)C2CCCC2C1 Chemical compound CC1=C(C)C2CCCC2C1 CFMFOFBPGJOQSR-UHFFFAOYSA-N 0.000 description 1
- HBJFQCBYCFIBOI-UHFFFAOYSA-N CC1=C(C)C=C2C(=C1)N=C(N1CCNCC1)N2CC1=CC=CC=C1 Chemical compound CC1=C(C)C=C2C(=C1)N=C(N1CCNCC1)N2CC1=CC=CC=C1 HBJFQCBYCFIBOI-UHFFFAOYSA-N 0.000 description 1
- DKMFGIBNBYNETD-UHFFFAOYSA-N CC1=C(C)N2C=CSC2=C1 Chemical compound CC1=C(C)N2C=CSC2=C1 DKMFGIBNBYNETD-UHFFFAOYSA-N 0.000 description 1
- BCHUIQRCIHMTQD-UHFFFAOYSA-N CC1=C(C)N2C=CSC2=N1 Chemical compound CC1=C(C)N2C=CSC2=N1 BCHUIQRCIHMTQD-UHFFFAOYSA-N 0.000 description 1
- UWDVZRPWFQFCFA-UHFFFAOYSA-N CC1=C(C)N2N=CSC2=N1 Chemical compound CC1=C(C)N2N=CSC2=N1 UWDVZRPWFQFCFA-UHFFFAOYSA-N 0.000 description 1
- WERWLKDELYCWDZ-UHFFFAOYSA-N CC1=C(C)N2N=NN=C2S1 Chemical compound CC1=C(C)N2N=NN=C2S1 WERWLKDELYCWDZ-UHFFFAOYSA-N 0.000 description 1
- RJFOKMSIDCLVTM-UHFFFAOYSA-N CC1=C2CCCC2ON1C Chemical compound CC1=C2CCCC2ON1C RJFOKMSIDCLVTM-UHFFFAOYSA-N 0.000 description 1
- WSLPBTYNOBZWIC-UHFFFAOYSA-N CC1=C2CCCN2CC1C Chemical compound CC1=C2CCCN2CC1C WSLPBTYNOBZWIC-UHFFFAOYSA-N 0.000 description 1
- UQXBURLSUCYNKY-UHFFFAOYSA-N CC1=C2CCNC2=NC=C1N Chemical compound CC1=C2CCNC2=NC=C1N UQXBURLSUCYNKY-UHFFFAOYSA-N 0.000 description 1
- RVSPEKCUSWTSCD-UHFFFAOYSA-N CC1=C2N=NCC2=CC=C1N Chemical compound CC1=C2N=NCC2=CC=C1N RVSPEKCUSWTSCD-UHFFFAOYSA-N 0.000 description 1
- CBTSYCADVMTKHK-UHFFFAOYSA-N CC1=C2N=S=NC2=CC=C1N Chemical compound CC1=C2N=S=NC2=CC=C1N CBTSYCADVMTKHK-UHFFFAOYSA-N 0.000 description 1
- GAMHHVABZFNPPG-UHFFFAOYSA-N CC1=CC2=NC=CN2N1C Chemical compound CC1=CC2=NC=CN2N1C GAMHHVABZFNPPG-UHFFFAOYSA-N 0.000 description 1
- NMRONBQQOFJQMI-UHFFFAOYSA-N CC1=CC=C(CN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)C=C1 Chemical compound CC1=CC=C(CN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)C=C1 NMRONBQQOFJQMI-UHFFFAOYSA-N 0.000 description 1
- VEFKMPXOOGXXSQ-UHFFFAOYSA-N CC1=CC=C2C(=C1)N=C(N1CCNCC1)N2CC1=CC=CC=C1 Chemical compound CC1=CC=C2C(=C1)N=C(N1CCNCC1)N2CC1=CC=CC=C1 VEFKMPXOOGXXSQ-UHFFFAOYSA-N 0.000 description 1
- OOOBGDSHHYTWFG-UHFFFAOYSA-N CC1=CC=C2C=CCC2=C1C Chemical compound CC1=CC=C2C=CCC2=C1C OOOBGDSHHYTWFG-UHFFFAOYSA-N 0.000 description 1
- OMEUGZPBAFYWGX-UHFFFAOYSA-N CC1=CC=C2C=COC2=C1C Chemical compound CC1=CC=C2C=COC2=C1C OMEUGZPBAFYWGX-UHFFFAOYSA-N 0.000 description 1
- ADDQFYLSEMVGPW-UHFFFAOYSA-N CC1=CC=C2C=CSC2=C1C Chemical compound CC1=CC=C2C=CSC2=C1C ADDQFYLSEMVGPW-UHFFFAOYSA-N 0.000 description 1
- VHXSIFLDVKFKDG-UHFFFAOYSA-N CC1=CC=C2NC=CC2=C1C Chemical compound CC1=CC=C2NC=CC2=C1C VHXSIFLDVKFKDG-UHFFFAOYSA-N 0.000 description 1
- HXICLUNGKDYXRL-UHFFFAOYSA-N CC1=CC=C2NN=NC2=C1C Chemical compound CC1=CC=C2NN=NC2=C1C HXICLUNGKDYXRL-UHFFFAOYSA-N 0.000 description 1
- BICFOGDDVXBEJA-UHFFFAOYSA-N CC1=CC=C2OC=CC2=C1C Chemical compound CC1=CC=C2OC=CC2=C1C BICFOGDDVXBEJA-UHFFFAOYSA-N 0.000 description 1
- SCDKHILCHXHUQX-UHFFFAOYSA-N CC1=CC=C2OCOC2=C1C Chemical compound CC1=CC=C2OCOC2=C1C SCDKHILCHXHUQX-UHFFFAOYSA-N 0.000 description 1
- LNHMCANPHUFGAT-UHFFFAOYSA-N CC1=CC=CC=C1CN1C(N2CCCNCC2)=NC2=C1C(=O)N(C)C(=O)N2C Chemical compound CC1=CC=CC=C1CN1C(N2CCCNCC2)=NC2=C1C(=O)N(C)C(=O)N2C LNHMCANPHUFGAT-UHFFFAOYSA-N 0.000 description 1
- BPNZHPDXOHHIHZ-UHFFFAOYSA-N CC1=CN2C=CSC2=C1C Chemical compound CC1=CN2C=CSC2=C1C BPNZHPDXOHHIHZ-UHFFFAOYSA-N 0.000 description 1
- FHZBVCZOBHIKJB-UHFFFAOYSA-N CC1=NC(CN2C(N3CCNCC3)=NC3=C2C(=O)NC(=O)N3C)=CS1 Chemical compound CC1=NC(CN2C(N3CCNCC3)=NC3=C2C(=O)NC(=O)N3C)=CS1 FHZBVCZOBHIKJB-UHFFFAOYSA-N 0.000 description 1
- QHQSASCSVWCXFV-UHFFFAOYSA-N CC1=NC2=C(SC=C2)N1C Chemical compound CC1=NC2=C(SC=C2)N1C QHQSASCSVWCXFV-UHFFFAOYSA-N 0.000 description 1
- UFTJQCJBBYYDLX-UHFFFAOYSA-N CC1=NN=C2C=CNN2C1C Chemical compound CC1=NN=C2C=CNN2C1C UFTJQCJBBYYDLX-UHFFFAOYSA-N 0.000 description 1
- MWVDOIYOOUPDCD-UHFFFAOYSA-N CC1C2=C(C=CS2)CCN1C Chemical compound CC1C2=C(C=CS2)CCN1C MWVDOIYOOUPDCD-UHFFFAOYSA-N 0.000 description 1
- GGIYFUMDDIHFHU-UHFFFAOYSA-N CC1C2=C(CCN1C)NC=C2 Chemical compound CC1C2=C(CCN1C)NC=C2 GGIYFUMDDIHFHU-UHFFFAOYSA-N 0.000 description 1
- STXBBQJVHYMRCA-UHFFFAOYSA-N CC1C2=C(CCN1C)OC=C2 Chemical compound CC1C2=C(CCN1C)OC=C2 STXBBQJVHYMRCA-UHFFFAOYSA-N 0.000 description 1
- QTXARSARJQRVQD-UHFFFAOYSA-N CC1C2=C(CCN1C)SC=C2 Chemical compound CC1C2=C(CCN1C)SC=C2 QTXARSARJQRVQD-UHFFFAOYSA-N 0.000 description 1
- ORZOUEVSAAWBDF-UHFFFAOYSA-N CC1CC2CCCC2C1C Chemical compound CC1CC2CCCC2C1C ORZOUEVSAAWBDF-UHFFFAOYSA-N 0.000 description 1
- BECSIHFZMLEFJM-UHFFFAOYSA-N CC1CNN2C=NN=C2C1C Chemical compound CC1CNN2C=NN=C2C1C BECSIHFZMLEFJM-UHFFFAOYSA-N 0.000 description 1
- FHIDPEUFJOUCRS-UHFFFAOYSA-N CCCC1=C(N2CCNCC2)C=CC=C1 Chemical compound CCCC1=C(N2CCNCC2)C=CC=C1 FHIDPEUFJOUCRS-UHFFFAOYSA-N 0.000 description 1
- ARDVRBRYSMFVPO-UHFFFAOYSA-N CCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(C#N)C=CC=C2)N(C)C1=O Chemical compound CCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(C#N)C=CC=C2)N(C)C1=O ARDVRBRYSMFVPO-UHFFFAOYSA-N 0.000 description 1
- SGWVFVNUZSMLQJ-UHFFFAOYSA-N CCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(C#N)C=CC=C2)N(CC2=CC=CC=C2)C1=O Chemical compound CCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(C#N)C=CC=C2)N(CC2=CC=CC=C2)C1=O SGWVFVNUZSMLQJ-UHFFFAOYSA-N 0.000 description 1
- OOJZPGFSLZCGHB-UHFFFAOYSA-N CCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2I)N(C)C1=O Chemical compound CCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2I)N(C)C1=O OOJZPGFSLZCGHB-UHFFFAOYSA-N 0.000 description 1
- IKXOFFFGTPLULJ-UHFFFAOYSA-N CCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2I)N(CC2=CC=CC=C2)C1=O Chemical compound CCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2I)N(CC2=CC=CC=C2)C1=O IKXOFFFGTPLULJ-UHFFFAOYSA-N 0.000 description 1
- DAMIFCSDOSBGPT-UHFFFAOYSA-N CCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C(C#N)C=CC=C2)N(C)C1=O Chemical compound CCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C(C#N)C=CC=C2)N(C)C1=O DAMIFCSDOSBGPT-UHFFFAOYSA-N 0.000 description 1
- UHQKILMVZSXOKY-UHFFFAOYSA-N CCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C(C#N)C=CC=C2)N(CC2=CC=CC=C2)C1=O Chemical compound CCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C(C#N)C=CC=C2)N(CC2=CC=CC=C2)C1=O UHQKILMVZSXOKY-UHFFFAOYSA-N 0.000 description 1
- YKXVBUBJYLKMOL-UHFFFAOYSA-N CCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2)N(C)C1=O YKXVBUBJYLKMOL-UHFFFAOYSA-N 0.000 description 1
- IHMUGTWSLVOXMM-UHFFFAOYSA-N CCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C1=O Chemical compound CCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C1=O IHMUGTWSLVOXMM-UHFFFAOYSA-N 0.000 description 1
- UCZBSOLWLMJVJE-UHFFFAOYSA-N CCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2I)N(C)C1=O Chemical compound CCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2I)N(C)C1=O UCZBSOLWLMJVJE-UHFFFAOYSA-N 0.000 description 1
- QHNLUOLQHACRMA-UHFFFAOYSA-N CCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2I)N(CC2=CC=CC=C2)C1=O Chemical compound CCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2I)N(CC2=CC=CC=C2)C1=O QHNLUOLQHACRMA-UHFFFAOYSA-N 0.000 description 1
- NTHAWSJFDJMXJT-UHFFFAOYSA-N CCN(CC)C(=O)CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C1=O Chemical compound CCN(CC)C(=O)CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C1=O NTHAWSJFDJMXJT-UHFFFAOYSA-N 0.000 description 1
- DBMQSLDYPZNWQX-UHFFFAOYSA-N CCOC(CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O)OCC Chemical compound CCOC(CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O)OCC DBMQSLDYPZNWQX-UHFFFAOYSA-N 0.000 description 1
- RIHCHHSHMVKYMJ-UHFFFAOYSA-N CCOCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O Chemical compound CCOCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O RIHCHHSHMVKYMJ-UHFFFAOYSA-N 0.000 description 1
- SDZUNFWODRWSPN-UHFFFAOYSA-N CCOCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(CC2=CC=CC=C2)C1=O Chemical compound CCOCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(CC2=CC=CC=C2)C1=O SDZUNFWODRWSPN-UHFFFAOYSA-N 0.000 description 1
- CNGJKAAPTBOPCF-UHFFFAOYSA-N CCOCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CCOCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(C)C1=O CNGJKAAPTBOPCF-UHFFFAOYSA-N 0.000 description 1
- HLWCVFLZGYBBLF-UHFFFAOYSA-N CCOCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O Chemical compound CCOCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O HLWCVFLZGYBBLF-UHFFFAOYSA-N 0.000 description 1
- YBJXRWANRTYCJE-UHFFFAOYSA-N CCOCCN1C(C2CCNCC2)=NC2=C1C=CC=C2 Chemical compound CCOCCN1C(C2CCNCC2)=NC2=C1C=CC=C2 YBJXRWANRTYCJE-UHFFFAOYSA-N 0.000 description 1
- BGYDYFZTTYHHAL-UHFFFAOYSA-N CCOCCN1C(N2CCNCC2)=NC2=C1C=CC=C2 Chemical compound CCOCCN1C(N2CCNCC2)=NC2=C1C=CC=C2 BGYDYFZTTYHHAL-UHFFFAOYSA-N 0.000 description 1
- XEOACQCALXGGQP-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCCNC(CO)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCCNC(CO)C3)N2CC2=CC=CC=C2)N(C)C1=O XEOACQCALXGGQP-UHFFFAOYSA-N 0.000 description 1
- PADMIJHSYFCEFT-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC3=CC=CC=C32)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC3=CC=CC=C32)N(C)C1=O PADMIJHSYFCEFT-UHFFFAOYSA-N 0.000 description 1
- JSWNZGOFKHAWGV-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(C)C1=O JSWNZGOFKHAWGV-UHFFFAOYSA-N 0.000 description 1
- JOLRDKJWSNCHRR-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2Br)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2Br)N(C)C1=O JOLRDKJWSNCHRR-UHFFFAOYSA-N 0.000 description 1
- XRIBCIOFSQNYHZ-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2C#N)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2C#N)N(C)C1=O XRIBCIOFSQNYHZ-UHFFFAOYSA-N 0.000 description 1
- CMHZHZMHFGHPCI-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2C(F)(F)F)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2C(F)(F)F)N(C)C1=O CMHZHZMHFGHPCI-UHFFFAOYSA-N 0.000 description 1
- JBFDJSHNNKJSAF-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2Cl)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2Cl)N(C)C1=O JBFDJSHNNKJSAF-UHFFFAOYSA-N 0.000 description 1
- SPSIXCAURMEGQP-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2I)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2I)N(C)C1=O SPSIXCAURMEGQP-UHFFFAOYSA-N 0.000 description 1
- MSDJALZVKJPBHM-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2[N+](=O)[O-])N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2[N+](=O)[O-])N(C)C1=O MSDJALZVKJPBHM-UHFFFAOYSA-N 0.000 description 1
- FXBTVWSOSGLTKO-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNC(CC4=C(O)C=CC=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNC(CC4=C(O)C=CC=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O FXBTVWSOSGLTKO-UHFFFAOYSA-N 0.000 description 1
- XWJPFOQAUBQIPS-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNC(CCC4=CC=CC=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNC(CCC4=CC=CC=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O XWJPFOQAUBQIPS-UHFFFAOYSA-N 0.000 description 1
- OQKFEXYHKKSJQG-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNC4(CC5CCC4C5)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNC4(CC5CCC4C5)C3)N2CC2=CC=CC=C2)N(C)C1=O OQKFEXYHKKSJQG-UHFFFAOYSA-N 0.000 description 1
- VEPCEEKGCCWCPJ-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNC4(CCCC4)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNC4(CCCC4)C3)N2CC2=CC=CC=C2)N(C)C1=O VEPCEEKGCCWCPJ-UHFFFAOYSA-N 0.000 description 1
- MTSZYBPWGIMCNR-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC(CC4=CC=CC=C4)C3)N2CC2=CC=CC=C2I)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC(CC4=CC=CC=C4)C3)N2CC2=CC=CC=C2I)N(C)C1=O MTSZYBPWGIMCNR-UHFFFAOYSA-N 0.000 description 1
- MQCZISPICSABGC-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC(CC4=CC=CC=N4)C3)N2CC2=CC=CC=C2Br)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC(CC4=CC=CC=N4)C3)N2CC2=CC=CC=C2Br)N(C)C1=O MQCZISPICSABGC-UHFFFAOYSA-N 0.000 description 1
- XSNSNRHAAWEWEI-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC(CC4=NC=CC=C4)C3)N2CC2=CC=CC=C2I)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC(CC4=NC=CC=C4)C3)N2CC2=CC=CC=C2I)N(C)C1=O XSNSNRHAAWEWEI-UHFFFAOYSA-N 0.000 description 1
- RRLWFBZULYMFIM-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC(CO)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC(CO)C3)N2CC2=CC=CC=C2)N(C)C1=O RRLWFBZULYMFIM-UHFFFAOYSA-N 0.000 description 1
- FURSBRLQELDELR-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC(O)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC(O)C3)N2CC2=CC=CC=C2)N(C)C1=O FURSBRLQELDELR-UHFFFAOYSA-N 0.000 description 1
- TUINWARGYHZQDA-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC(=O)N2CCCC2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC(=O)N2CCCC2)N(C)C1=O TUINWARGYHZQDA-UHFFFAOYSA-N 0.000 description 1
- PDAWFZNRCUSIFJ-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C([NH+]([O-])O)C=CC=C2F)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C([NH+]([O-])O)C=CC=C2F)N(C)C1=O PDAWFZNRCUSIFJ-UHFFFAOYSA-N 0.000 description 1
- DDXUHHBMYLOMJQ-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC(Cl)=CC=C2[N+](=O)[O-])N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC(Cl)=CC=C2[N+](=O)[O-])N(C)C1=O DDXUHHBMYLOMJQ-UHFFFAOYSA-N 0.000 description 1
- AUDGXLGJGSACKY-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC3=C(C=CC=C3)C=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC3=C(C=CC=C3)C=C2)N(C)C1=O AUDGXLGJGSACKY-UHFFFAOYSA-N 0.000 description 1
- IWKDPLLNUIDGOF-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(C#N)C=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(C#N)C=C2)N(C)C1=O IWKDPLLNUIDGOF-UHFFFAOYSA-N 0.000 description 1
- XLTDIXNGQNKIJS-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(C(C)(C)C)C=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(C(C)(C)C)C=C2)N(C)C1=O XLTDIXNGQNKIJS-UHFFFAOYSA-N 0.000 description 1
- DOTJJCPEGRLPKG-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(C(F)(F)F)C=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(C(F)(F)F)C=C2)N(C)C1=O DOTJJCPEGRLPKG-UHFFFAOYSA-N 0.000 description 1
- LPEVDFICEYSMRJ-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(C3=CC=CC=C3)C=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(C3=CC=CC=C3)C=C2)N(C)C1=O LPEVDFICEYSMRJ-UHFFFAOYSA-N 0.000 description 1
- MUWCAZJOWUNWBF-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(C3=CSN=N3)C=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(C3=CSN=N3)C=C2)N(C)C1=O MUWCAZJOWUNWBF-UHFFFAOYSA-N 0.000 description 1
- CYYCNDISYWTPJK-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(Cl)C(Cl)=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(Cl)C(Cl)=C2)N(C)C1=O CYYCNDISYWTPJK-UHFFFAOYSA-N 0.000 description 1
- NIVZGQOLOXPLPJ-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(Cl)C=C2Cl)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(Cl)C=C2Cl)N(C)C1=O NIVZGQOLOXPLPJ-UHFFFAOYSA-N 0.000 description 1
- OLBSWCPPNRDGHV-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(OC(F)(F)F)C=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(OC(F)(F)F)C=C2)N(C)C1=O OLBSWCPPNRDGHV-UHFFFAOYSA-N 0.000 description 1
- YNWZYDDOWBGNJA-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(OCC3=CC=CC=C3)C=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(OCC3=CC=CC=C3)C=C2)N(C)C1=O YNWZYDDOWBGNJA-UHFFFAOYSA-N 0.000 description 1
- LFPQTPGHRXOWQE-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(S(C)(=O)=O)C=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=C(S(C)(=O)=O)C=C2)N(C)C1=O LFPQTPGHRXOWQE-UHFFFAOYSA-N 0.000 description 1
- FIYVUQJPOVRHOW-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC(Br)=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC(Br)=C2)N(C)C1=O FIYVUQJPOVRHOW-UHFFFAOYSA-N 0.000 description 1
- RFOQPGZBMDFBEQ-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC3=C2C=CC=C3)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC3=C2C=CC=C3)N(C)C1=O RFOQPGZBMDFBEQ-UHFFFAOYSA-N 0.000 description 1
- QFSMMXJBEBXTJP-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2)N(C)C1=O QFSMMXJBEBXTJP-UHFFFAOYSA-N 0.000 description 1
- IXKJEHCNDGRQIE-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2C#N)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2C#N)N(C)C1=O IXKJEHCNDGRQIE-UHFFFAOYSA-N 0.000 description 1
- VCPMPUPMTXJKOP-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2C(F)(F)F)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2C(F)(F)F)N(C)C1=O VCPMPUPMTXJKOP-UHFFFAOYSA-N 0.000 description 1
- ZWWQXABLXZRLHQ-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2C2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2C2=CC=CC=C2)N(C)C1=O ZWWQXABLXZRLHQ-UHFFFAOYSA-N 0.000 description 1
- CAJKDPDHZJIDTN-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2OC(F)(F)F)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2OC(F)(F)F)N(C)C1=O CAJKDPDHZJIDTN-UHFFFAOYSA-N 0.000 description 1
- FGLVRZOGQIYUNT-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2OC(F)F)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2OC(F)F)N(C)C1=O FGLVRZOGQIYUNT-UHFFFAOYSA-N 0.000 description 1
- XPLGFGQUGAMMFE-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2SC(F)(F)F)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2SC(F)(F)F)N(C)C1=O XPLGFGQUGAMMFE-UHFFFAOYSA-N 0.000 description 1
- WNAQNKUVYWGXJY-UHFFFAOYSA-N CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2CCCCC2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2CCCCC2)N(C)C1=O WNAQNKUVYWGXJY-UHFFFAOYSA-N 0.000 description 1
- ANTRLZZSHHSNLE-FQEVSTJZSA-N CN1C(=O)C2=C(N=C(N3CCN[C@@H](CC4=CC=CC=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCN[C@@H](CC4=CC=CC=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O ANTRLZZSHHSNLE-FQEVSTJZSA-N 0.000 description 1
- FFRYEFLPFGXVSV-OAQYLSRUSA-N CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=C(C#N)C=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=C(C#N)C=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O FFRYEFLPFGXVSV-OAQYLSRUSA-N 0.000 description 1
- KTSVPYMTYULGDU-HXUWFJFHSA-N CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=C(F)C=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=C(F)C=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O KTSVPYMTYULGDU-HXUWFJFHSA-N 0.000 description 1
- FADGWZGGARZQRH-LJQANCHMSA-N CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=C(O)C=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=C(O)C=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O FADGWZGGARZQRH-LJQANCHMSA-N 0.000 description 1
- QDXAPGNJTPGZEA-LJQANCHMSA-N CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=C([NH+]([O-])O)C=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=C([NH+]([O-])O)C=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O QDXAPGNJTPGZEA-LJQANCHMSA-N 0.000 description 1
- ANTRLZZSHHSNLE-HXUWFJFHSA-N CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=CC=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=CC=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O ANTRLZZSHHSNLE-HXUWFJFHSA-N 0.000 description 1
- FRWDQHBRKHYONF-HXUWFJFHSA-N CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=CC=C4)C3)N2CC2=NC=C(C#N)C=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=CC=C4)C3)N2CC2=NC=C(C#N)C=C2)N(C)C1=O FRWDQHBRKHYONF-HXUWFJFHSA-N 0.000 description 1
- KMZQRUPUJWTKOJ-GOSISDBHSA-N CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=CS4)C3)N2CC2=CC=CC=C2C#N)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CC=CS4)C3)N2CC2=CC=CC=C2C#N)N(C)C1=O KMZQRUPUJWTKOJ-GOSISDBHSA-N 0.000 description 1
- VYJVCJURPANQIE-MRXNPFEDSA-N CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CSC=N4)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCN[C@H](CC4=CSC=N4)C3)N2CC2=CC=CC=C2)N(C)C1=O VYJVCJURPANQIE-MRXNPFEDSA-N 0.000 description 1
- GWDVHHPRJSAZBM-AWEZNQCLSA-N CN1C(=O)C2=C(N=C(N3CCN[C@H](CO)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCN[C@H](CO)C3)N2CC2=CC=CC=C2)N(C)C1=O GWDVHHPRJSAZBM-AWEZNQCLSA-N 0.000 description 1
- ZKYFKZYTOZKYDQ-NRFANRHFSA-N CN1C(=O)C2=C(N=C(N3CCN[C@H](COCC4=CC=CC=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O Chemical compound CN1C(=O)C2=C(N=C(N3CCN[C@H](COCC4=CC=CC=C4)C3)N2CC2=CC=CC=C2)N(C)C1=O ZKYFKZYTOZKYDQ-NRFANRHFSA-N 0.000 description 1
- ABDBLPAYLUKXBO-UHFFFAOYSA-N CN1C(=O)N(CC#N)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 Chemical compound CN1C(=O)N(CC#N)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 ABDBLPAYLUKXBO-UHFFFAOYSA-N 0.000 description 1
- SHIKPAHPUOTSAR-UHFFFAOYSA-N CN1C(=O)N(CC(=O)C2=CC=CC=C2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 Chemical compound CN1C(=O)N(CC(=O)C2=CC=CC=C2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 SHIKPAHPUOTSAR-UHFFFAOYSA-N 0.000 description 1
- DVBRSHAHXJTIAH-UHFFFAOYSA-N CN1C(=O)N(CC(O)CO)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CC(O)CO)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 DVBRSHAHXJTIAH-UHFFFAOYSA-N 0.000 description 1
- NPJXQLXQBXSUSV-UHFFFAOYSA-N CN1C(=O)N(CC(O)CO)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CC(O)CO)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 NPJXQLXQBXSUSV-UHFFFAOYSA-N 0.000 description 1
- ATQGSDYBRSUYDT-UHFFFAOYSA-N CN1C(=O)N(CC2=C(C#N)C=CC=C2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 Chemical compound CN1C(=O)N(CC2=C(C#N)C=CC=C2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 ATQGSDYBRSUYDT-UHFFFAOYSA-N 0.000 description 1
- UNJNZRORNSBYLI-UHFFFAOYSA-N CN1C(=O)N(CC2=CC=CC(OC(F)(F)F)=C2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CC2=CC=CC(OC(F)(F)F)=C2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 UNJNZRORNSBYLI-UHFFFAOYSA-N 0.000 description 1
- YUCGPEKPTLIAMT-UHFFFAOYSA-N CN1C(=O)N(CC2=CC=CC(OC(F)(F)F)=C2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CC2=CC=CC(OC(F)(F)F)=C2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 YUCGPEKPTLIAMT-UHFFFAOYSA-N 0.000 description 1
- DHKVFXHJILVMAO-UHFFFAOYSA-N CN1C(=O)N(CC2CCCCO2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CC2CCCCO2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 DHKVFXHJILVMAO-UHFFFAOYSA-N 0.000 description 1
- GUJLIQSCZYTZGX-UHFFFAOYSA-N CN1C(=O)N(CC2CCCO2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CC2CCCO2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 GUJLIQSCZYTZGX-UHFFFAOYSA-N 0.000 description 1
- MMTIJDQFBVVAMQ-UHFFFAOYSA-N CN1C(=O)N(CC2CCCO2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 Chemical compound CN1C(=O)N(CC2CCCO2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 MMTIJDQFBVVAMQ-UHFFFAOYSA-N 0.000 description 1
- JLYQREMFFLYFIF-UHFFFAOYSA-N CN1C(=O)N(CC2CCCO2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CC2CCCO2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 JLYQREMFFLYFIF-UHFFFAOYSA-N 0.000 description 1
- CMBGVCOANBXXBH-UHFFFAOYSA-N CN1C(=O)N(CCC2CCCCC2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 Chemical compound CN1C(=O)N(CCC2CCCCC2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 CMBGVCOANBXXBH-UHFFFAOYSA-N 0.000 description 1
- ZZGCNTSOJILLEE-UHFFFAOYSA-N CN1C(=O)N(CCC2OCCCO2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CCC2OCCCO2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 ZZGCNTSOJILLEE-UHFFFAOYSA-N 0.000 description 1
- YJXVYRTXEWNXBU-UHFFFAOYSA-N CN1C(=O)N(CCC2OCCCO2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CCC2OCCCO2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 YJXVYRTXEWNXBU-UHFFFAOYSA-N 0.000 description 1
- XWQYLOAJGPLLOH-UHFFFAOYSA-N CN1C(=O)N(CCC2OCCO2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CCC2OCCO2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 XWQYLOAJGPLLOH-UHFFFAOYSA-N 0.000 description 1
- LFRBEBHGMGBNJA-UHFFFAOYSA-N CN1C(=O)N(CCC2OCCO2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CCC2OCCO2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 LFRBEBHGMGBNJA-UHFFFAOYSA-N 0.000 description 1
- SKZMGOQYJIYLJU-UHFFFAOYSA-N CN1C(=O)N(CCCO)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CCCO)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 SKZMGOQYJIYLJU-UHFFFAOYSA-N 0.000 description 1
- JUSWREQXOXPHMZ-UHFFFAOYSA-N CN1C(=O)N(CCCO)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 Chemical compound CN1C(=O)N(CCCO)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1 JUSWREQXOXPHMZ-UHFFFAOYSA-N 0.000 description 1
- JTHDTFWKDJQQNT-UHFFFAOYSA-N CN1C(=O)N(CCCO)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CCCO)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 JTHDTFWKDJQQNT-UHFFFAOYSA-N 0.000 description 1
- WGGDCZLNSXISHJ-UHFFFAOYSA-N CN1C(=O)N(CCCOC2CCCCO2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CCCOC2CCCCO2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 WGGDCZLNSXISHJ-UHFFFAOYSA-N 0.000 description 1
- KVAXGPRMKZKOMP-UHFFFAOYSA-N CN1C(=O)N(CCF)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CCF)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 KVAXGPRMKZKOMP-UHFFFAOYSA-N 0.000 description 1
- RYNSDHRRCXUHDS-UHFFFAOYSA-N CN1C(=O)N(CCOC2=CC=CC=C2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CCOC2=CC=CC=C2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 RYNSDHRRCXUHDS-UHFFFAOYSA-N 0.000 description 1
- BCJMJXVRYWGBFN-UHFFFAOYSA-N CN1C(=O)N(CCOC2=CC=CC=C2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CCOC2=CC=CC=C2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 BCJMJXVRYWGBFN-UHFFFAOYSA-N 0.000 description 1
- NUSSXFXNDIYJNA-UHFFFAOYSA-N CN1C(=O)N(CCOCC2=CC=CC=C2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CCOCC2=CC=CC=C2)C(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(I)C=CC=C1 NUSSXFXNDIYJNA-UHFFFAOYSA-N 0.000 description 1
- QFGPYFWLXPBQIP-UHFFFAOYSA-N CN1C(=O)N(CCOCC2=CC=CC=C2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 Chemical compound CN1C(=O)N(CCOCC2=CC=CC=C2)C(=O)C2=C1N=C(N1CCNCC1)N2CC1=C(I)C=CC=C1 QFGPYFWLXPBQIP-UHFFFAOYSA-N 0.000 description 1
- MBZXPYYVBJVMCQ-UHFFFAOYSA-N CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC(=O)C1=CC=CC=C1 Chemical compound CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC(=O)C1=CC=CC=C1 MBZXPYYVBJVMCQ-UHFFFAOYSA-N 0.000 description 1
- BPLFRVBSZYCWQV-UHFFFAOYSA-N CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(C#N)C=CC=C1 Chemical compound CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC1=C(C#N)C=CC=C1 BPLFRVBSZYCWQV-UHFFFAOYSA-N 0.000 description 1
- SPQSMUBJSLJCEW-UHFFFAOYSA-N CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1Br Chemical compound CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1Br SPQSMUBJSLJCEW-UHFFFAOYSA-N 0.000 description 1
- BBWPIYLOSRGZMP-UHFFFAOYSA-N CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1Cl Chemical compound CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1Cl BBWPIYLOSRGZMP-UHFFFAOYSA-N 0.000 description 1
- PUYLGCCLEODMTE-UHFFFAOYSA-N CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1I Chemical compound CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CC1=CC=CC=C1I PUYLGCCLEODMTE-UHFFFAOYSA-N 0.000 description 1
- CFNINJAIQCKVJU-UHFFFAOYSA-N CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CCC1=CC=CC=C1 Chemical compound CN1C(=O)NC(=O)C2=C1N=C(N1CCCNCC1)N2CCC1=CC=CC=C1 CFNINJAIQCKVJU-UHFFFAOYSA-N 0.000 description 1
- QSLFJGRSVHGYDS-UHFFFAOYSA-N CN1C(=O)NC(=O)C2=C1N=C(N1CCNCC1)N2CC(=O)C1=CC=CC=C1 Chemical compound CN1C(=O)NC(=O)C2=C1N=C(N1CCNCC1)N2CC(=O)C1=CC=CC=C1 QSLFJGRSVHGYDS-UHFFFAOYSA-N 0.000 description 1
- OSWQQKHGTFZUND-UHFFFAOYSA-N CN1C(=O)NC(=O)C2=C1N=C(N1CCNCC1)N2CC1=CC=CC=C1 Chemical compound CN1C(=O)NC(=O)C2=C1N=C(N1CCNCC1)N2CC1=CC=CC=C1 OSWQQKHGTFZUND-UHFFFAOYSA-N 0.000 description 1
- HBJFRCIMFSKUQJ-UHFFFAOYSA-N CN1C(=O)NC(=O)C2=C1N=C(N1CCNCC1)N2CC1=CC=CC=C1I Chemical compound CN1C(=O)NC(=O)C2=C1N=C(N1CCNCC1)N2CC1=CC=CC=C1I HBJFRCIMFSKUQJ-UHFFFAOYSA-N 0.000 description 1
- WNVROUIPADYYDI-UHFFFAOYSA-N CN1C(=O)NC(=O)C2=C1NC(N1CCNCC1)N2CC(O)C1=CC=C(N(=O)=O)C=C1 Chemical compound CN1C(=O)NC(=O)C2=C1NC(N1CCNCC1)N2CC(O)C1=CC=C(N(=O)=O)C=C1 WNVROUIPADYYDI-UHFFFAOYSA-N 0.000 description 1
- BIQXNLYEZUBQOA-UHFFFAOYSA-N CN1C(N)=NC=C2N=CN=C21 Chemical compound CN1C(N)=NC=C2N=CN=C21 BIQXNLYEZUBQOA-UHFFFAOYSA-N 0.000 description 1
- ZRXNHXKAVNGUNR-UHFFFAOYSA-N CN1C(N2CCNC2)=NC2=C1C(=O)NC(=O)N2 Chemical compound CN1C(N2CCNC2)=NC2=C1C(=O)NC(=O)N2 ZRXNHXKAVNGUNR-UHFFFAOYSA-N 0.000 description 1
- XOHFEKGTLDNEFO-UHFFFAOYSA-N COC(=O)C(C1=CC=CC=C1)N1C(N2CCNCC2)=NC2=C1C(=O)N(C)C(=O)N2C Chemical compound COC(=O)C(C1=CC=CC=C1)N1C(N2CCNCC2)=NC2=C1C(=O)N(C)C(=O)N2C XOHFEKGTLDNEFO-UHFFFAOYSA-N 0.000 description 1
- XGNPSKXFPSPTDE-UHFFFAOYSA-N COC(=O)C1=C(N2CCNCC2)C=CC=C1 Chemical compound COC(=O)C1=C(N2CCNCC2)C=CC=C1 XGNPSKXFPSPTDE-UHFFFAOYSA-N 0.000 description 1
- GOPZBZBOICZBNI-UHFFFAOYSA-N COC(=O)C1=CC(CN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)=CC=C1 Chemical compound COC(=O)C1=CC(CN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)=CC=C1 GOPZBZBOICZBNI-UHFFFAOYSA-N 0.000 description 1
- NQMPLCKIYDDBDS-UHFFFAOYSA-N COC(=O)C1=CC=C(CN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)C=C1 Chemical compound COC(=O)C1=CC=C(CN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)C=C1 NQMPLCKIYDDBDS-UHFFFAOYSA-N 0.000 description 1
- ZFACJYCETZHQFY-UHFFFAOYSA-N COC(=O)C1=CC=CN=C1N1CCNCC1 Chemical compound COC(=O)C1=CC=CN=C1N1CCNCC1 ZFACJYCETZHQFY-UHFFFAOYSA-N 0.000 description 1
- ZUKNCPFVAYHFBY-UHFFFAOYSA-N COC(CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O)OC Chemical compound COC(CN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O)OC ZUKNCPFVAYHFBY-UHFFFAOYSA-N 0.000 description 1
- SKJBPVRMHJFCDG-UHFFFAOYSA-N COC1=C(CC2CN(C3=NC4=C(C(=O)N(C)C(=O)N4C)N3CC3=CC=CC=C3)CCN2)C=CC=C1 Chemical compound COC1=C(CC2CN(C3=NC4=C(C(=O)N(C)C(=O)N4C)N3CC3=CC=CC=C3)CCN2)C=CC=C1 SKJBPVRMHJFCDG-UHFFFAOYSA-N 0.000 description 1
- YLYLGNKNHCKNRS-UHFFFAOYSA-N COC1=C(OC)C(CN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)=CC=C1 Chemical compound COC1=C(OC)C(CN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)=CC=C1 YLYLGNKNHCKNRS-UHFFFAOYSA-N 0.000 description 1
- OEYYBTWYWCTDKU-UHFFFAOYSA-N COC1=C2C(=CC=C1)N=C(N1CCNCC1)N2CC1=CC=CC=C1 Chemical compound COC1=C2C(=CC=C1)N=C(N1CCNCC1)N2CC1=CC=CC=C1 OEYYBTWYWCTDKU-UHFFFAOYSA-N 0.000 description 1
- FJJDFWFMTJCZBG-UHFFFAOYSA-N COC1=CC(C(=O)OCCN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)=CC(OC)=C1OC Chemical compound COC1=CC(C(=O)OCCN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)=CC(OC)=C1OC FJJDFWFMTJCZBG-UHFFFAOYSA-N 0.000 description 1
- PTQOFHROJXEPIY-UHFFFAOYSA-N COC1=CC(CN2C(=O)C3=C(N=C(N4CCCNCC4)N3CC3=C(I)C=CC=C3)N(C)C2=O)=CC(OC)=C1 Chemical compound COC1=CC(CN2C(=O)C3=C(N=C(N4CCCNCC4)N3CC3=C(I)C=CC=C3)N(C)C2=O)=CC(OC)=C1 PTQOFHROJXEPIY-UHFFFAOYSA-N 0.000 description 1
- PXWSAFVUSQXZBR-UHFFFAOYSA-N COC1=CC=C(CC2=C(C3CCNCC3)C=CC=C2)C=C1 Chemical compound COC1=CC=C(CC2=C(C3CCNCC3)C=CC=C2)C=C1 PXWSAFVUSQXZBR-UHFFFAOYSA-N 0.000 description 1
- RRNBOXVRQBNZGX-UHFFFAOYSA-N COC1=CC=C(CN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)C=C1 Chemical compound COC1=CC=C(CN2C(N3CCNCC3)=NC3=C2C(=O)N(C)C(=O)N3C)C=C1 RRNBOXVRQBNZGX-UHFFFAOYSA-N 0.000 description 1
- LLUHUSTYHAMQBA-HXUWFJFHSA-N COC1=CC=C(C[C@@H]2CN(C3=NC4=C(C(=O)N(C)C(=O)N4C)N3CC3=CC=CC=C3)CCN2)C=C1 Chemical compound COC1=CC=C(C[C@@H]2CN(C3=NC4=C(C(=O)N(C)C(=O)N4C)N3CC3=CC=CC=C3)CCN2)C=C1 LLUHUSTYHAMQBA-HXUWFJFHSA-N 0.000 description 1
- FWYSFXFCGNZNMX-UHFFFAOYSA-N COC1=CC=C2N=C(N3CCNCC3)N(CC3=CC=CC=C3)C2=C1 Chemical compound COC1=CC=C2N=C(N3CCNCC3)N(CC3=CC=CC=C3)C2=C1 FWYSFXFCGNZNMX-UHFFFAOYSA-N 0.000 description 1
- LZCAZOJSGPUTCG-UHFFFAOYSA-N COC1=CC=CC(CN2C(=O)C3=C(N=C(N4CCCNCC4)N3CC3=C(I)C=CC=C3)N(C)C2=O)=C1 Chemical compound COC1=CC=CC(CN2C(=O)C3=C(N=C(N4CCCNCC4)N3CC3=C(I)C=CC=C3)N(C)C2=O)=C1 LZCAZOJSGPUTCG-UHFFFAOYSA-N 0.000 description 1
- NQOBMESKNSOHRV-UHFFFAOYSA-N COC1=CC=CC(CN2C(=O)C3=C(N=C(N4CCNCC4)N3CC3=C(I)C=CC=C3)N(C)C2=O)=C1 Chemical compound COC1=CC=CC(CN2C(=O)C3=C(N=C(N4CCNCC4)N3CC3=C(I)C=CC=C3)N(C)C2=O)=C1 NQOBMESKNSOHRV-UHFFFAOYSA-N 0.000 description 1
- RQUXMKSKGVLZTG-UHFFFAOYSA-N COC1=CC=CC=C1CN1C(N2CCCNCC2)=NC2=C1C(=O)N(C)C(=O)N2C Chemical compound COC1=CC=CC=C1CN1C(N2CCCNCC2)=NC2=C1C(=O)N(C)C(=O)N2C RQUXMKSKGVLZTG-UHFFFAOYSA-N 0.000 description 1
- JWAGDOQXWWMGQI-UHFFFAOYSA-N COCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O Chemical compound COCCN1C(=O)C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O JWAGDOQXWWMGQI-UHFFFAOYSA-N 0.000 description 1
- NSCXITDZJATTGU-UHFFFAOYSA-N COCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O Chemical compound COCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O NSCXITDZJATTGU-UHFFFAOYSA-N 0.000 description 1
- KDHWZUVBTLDSGX-UHFFFAOYSA-N COCCOCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O Chemical compound COCCOCCN1C(=O)C2=C(N=C(N3CCNCC3)N2CC2=C(I)C=CC=C2)N(C)C1=O KDHWZUVBTLDSGX-UHFFFAOYSA-N 0.000 description 1
- RGJWYPAWXHIEGX-OKILXGFUSA-N C[C@H]1CN(C2=NC3=C(C(=O)N(C)C(=O)N3C)N2CC2=CC=CC=C2)C[C@@H](C)N1 Chemical compound C[C@H]1CN(C2=NC3=C(C(=O)N(C)C(=O)N3C)N2CC2=CC=CC=C2)C[C@@H](C)N1 RGJWYPAWXHIEGX-OKILXGFUSA-N 0.000 description 1
- XFUOIMWLAPSVGQ-UHFFFAOYSA-N ClC1=C(Cl)C=C2C(=C1)N=C(N1CCNCC1)N2CC1=CC=CC=C1 Chemical compound ClC1=C(Cl)C=C2C(=C1)N=C(N1CCNCC1)N2CC1=CC=CC=C1 XFUOIMWLAPSVGQ-UHFFFAOYSA-N 0.000 description 1
- RDAXAGXJSCEYLT-UHFFFAOYSA-N ClC1=CC=C2C(=C1)N=C(N1CCNCC1)N2CC1=CC=CC=C1 Chemical compound ClC1=CC=C2C(=C1)N=C(N1CCNCC1)N2CC1=CC=CC=C1 RDAXAGXJSCEYLT-UHFFFAOYSA-N 0.000 description 1
- VZUBMIDXJRGARE-UHFFFAOYSA-N FC(F)(F)C1=C(N2CCNCC2)C=CC=C1 Chemical compound FC(F)(F)C1=C(N2CCNCC2)C=CC=C1 VZUBMIDXJRGARE-UHFFFAOYSA-N 0.000 description 1
- HOGJVIXWTXJVOF-UHFFFAOYSA-N FC1=CC=C(CC2=CC=CC=C2C2CCNCC2)C=C1 Chemical compound FC1=CC=C(CC2=CC=CC=C2C2CCNCC2)C=C1 HOGJVIXWTXJVOF-UHFFFAOYSA-N 0.000 description 1
- IEXAFRUCIULFQM-UHFFFAOYSA-N N#CC1=C(CN2C(N3CCCNCC3)=NC3=C2C(=O)NC(=O)N3CC2=CC=CC=C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(N3CCCNCC3)=NC3=C2C(=O)NC(=O)N3CC2=CC=CC=C2)C=CC=C1 IEXAFRUCIULFQM-UHFFFAOYSA-N 0.000 description 1
- FQNCNHMYMXLKJN-UHFFFAOYSA-N N#CC1=C(CN2C(N3CCNCC3)=NC3=C2C(=O)NC(=O)N3CC2=CC=CC=C2)C=CC=C1 Chemical compound N#CC1=C(CN2C(N3CCNCC3)=NC3=C2C(=O)NC(=O)N3CC2=CC=CC=C2)C=CC=C1 FQNCNHMYMXLKJN-UHFFFAOYSA-N 0.000 description 1
- RYNARQDUUQTTFJ-UHFFFAOYSA-N NC(=O)C1=CC=CN=C1N1CCNCC1 Chemical compound NC(=O)C1=CC=CN=C1N1CCNCC1 RYNARQDUUQTTFJ-UHFFFAOYSA-N 0.000 description 1
- ZEDYIJYPOSFIOZ-UHFFFAOYSA-N O=C(C1=CC=CC=C1)C1=CC(N(=O)=O)=CC=C1N1CCNCC1 Chemical compound O=C(C1=CC=CC=C1)C1=CC(N(=O)=O)=CC=C1N1CCNCC1 ZEDYIJYPOSFIOZ-UHFFFAOYSA-N 0.000 description 1
- FITOMBDCAHKKEV-UHFFFAOYSA-N O=C1C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(CC2=CC=CC=C2)C(=O)N1CCCO Chemical compound O=C1C2=C(N=C(N3CCCNCC3)N2CC2=C(I)C=CC=C2)N(CC2=CC=CC=C2)C(=O)N1CCCO FITOMBDCAHKKEV-UHFFFAOYSA-N 0.000 description 1
- PXFNLWLXKDYPPC-UHFFFAOYSA-N O=C1C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C(=O)N1CC1=CC=CC=C1 Chemical compound O=C1C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C(=O)N1CC1=CC=CC=C1 PXFNLWLXKDYPPC-UHFFFAOYSA-N 0.000 description 1
- GPJWBLBMRFZPJJ-UHFFFAOYSA-N O=C1C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C(=O)N1CCO Chemical compound O=C1C2=C(N=C(N3CCCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C(=O)N1CCO GPJWBLBMRFZPJJ-UHFFFAOYSA-N 0.000 description 1
- RAIXEGWBDXUGCZ-UHFFFAOYSA-N O=C1C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C(=O)N1CC1=CC=CC=C1 Chemical compound O=C1C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C(=O)N1CC1=CC=CC=C1 RAIXEGWBDXUGCZ-UHFFFAOYSA-N 0.000 description 1
- IUTLQECRZFAVCC-UHFFFAOYSA-N O=C1C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C(=O)N1CCO Chemical compound O=C1C2=C(N=C(N3CCNCC3)N2CC2=CC=CC=C2)N(CC2=CC=CC=C2)C(=O)N1CCO IUTLQECRZFAVCC-UHFFFAOYSA-N 0.000 description 1
- HUWDKUCQBWWICY-UHFFFAOYSA-N O=C1NC(=O)N(CC2=CC=CC=C2)C2=C1N(CC1=CC=CC=C1)C(N1CCNCC1)=N2 Chemical compound O=C1NC(=O)N(CC2=CC=CC=C2)C2=C1N(CC1=CC=CC=C1)C(N1CCNCC1)=N2 HUWDKUCQBWWICY-UHFFFAOYSA-N 0.000 description 1
- NFKOOVKWNUMEQY-UHFFFAOYSA-N O=C1NC(=O)N(CC2=CC=CC=C2)C2=C1N(CC1=CC=CC=C1C(F)(F)F)C(N1CCNCC1)=N2 Chemical compound O=C1NC(=O)N(CC2=CC=CC=C2)C2=C1N(CC1=CC=CC=C1C(F)(F)F)C(N1CCNCC1)=N2 NFKOOVKWNUMEQY-UHFFFAOYSA-N 0.000 description 1
- NOWIILLDHUPAOI-UHFFFAOYSA-N O=C1NC(=O)N(CC2=CC=CC=C2)C2=C1N(CC1=CC=CC=C1I)C(N1CCCNCC1)=N2 Chemical compound O=C1NC(=O)N(CC2=CC=CC=C2)C2=C1N(CC1=CC=CC=C1I)C(N1CCCNCC1)=N2 NOWIILLDHUPAOI-UHFFFAOYSA-N 0.000 description 1
- WQACCWREPPVZEE-UHFFFAOYSA-N O=C1NC(=O)N(CC2=CC=CC=C2)C2=C1N(CC1=CC=CC=C1I)C(N1CCNCC1)=N2 Chemical compound O=C1NC(=O)N(CC2=CC=CC=C2)C2=C1N(CC1=CC=CC=C1I)C(N1CCNCC1)=N2 WQACCWREPPVZEE-UHFFFAOYSA-N 0.000 description 1
- HVPCSXHMLGSQSS-UHFFFAOYSA-N O=C1NC(=O)N(CC2=CC=CC=C2)C2=C1N(CCC1=CC=CC=C1)C(N1CCNCC1)=N2 Chemical compound O=C1NC(=O)N(CC2=CC=CC=C2)C2=C1N(CCC1=CC=CC=C1)C(N1CCNCC1)=N2 HVPCSXHMLGSQSS-UHFFFAOYSA-N 0.000 description 1
- GBIHCCAAGLOCEZ-UHFFFAOYSA-N OC1=CC=C2C(=C1)N=C(N1CCNCC1)N2CC1=CC=CC=C1 Chemical compound OC1=CC=C2C(=C1)N=C(N1CCNCC1)N2CC1=CC=CC=C1 GBIHCCAAGLOCEZ-UHFFFAOYSA-N 0.000 description 1
- HLYAGHNCWJSUKC-UHFFFAOYSA-N OC1=CC=C2N=C(N3CCNCC3)N(CC3=CC=CC=C3)C2=C1.[H]Br Chemical compound OC1=CC=C2N=C(N3CCNCC3)N(CC3=CC=CC=C3)C2=C1.[H]Br HLYAGHNCWJSUKC-UHFFFAOYSA-N 0.000 description 1
- ASBVLJIRSGFRCR-BBBLOLIVSA-N [H][C@@]12C/C=C\[C@]1([H])C=C(C)[C@H]2C Chemical compound [H][C@@]12C/C=C\[C@]1([H])C=C(C)[C@H]2C ASBVLJIRSGFRCR-BBBLOLIVSA-N 0.000 description 1
- QDDHLJQJXCJNGW-YUMQZZPRSA-N [H][C@@]12CCCN1CON(C)[C@H]2C Chemical compound [H][C@@]12CCCN1CON(C)[C@H]2C QDDHLJQJXCJNGW-YUMQZZPRSA-N 0.000 description 1
- GYGOFTXACXTBEK-QWRGUYRKSA-N [H][C@@]12CCC[C@@]1([H])C(C)=C(C)CC2 Chemical compound [H][C@@]12CCC[C@@]1([H])C(C)=C(C)CC2 GYGOFTXACXTBEK-QWRGUYRKSA-N 0.000 description 1
- GYGOFTXACXTBEK-MNOVXSKESA-N [H][C@]12CCC[C@@]1([H])C(C)=C(C)CC2 Chemical compound [H][C@]12CCC[C@@]1([H])C(C)=C(C)CC2 GYGOFTXACXTBEK-MNOVXSKESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Definitions
- the present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity, as well as methods for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity.
- DPP-IV Dipeptidyl peptidase-IV
- DPP-IV serine protease belonging to the group of post-proline/alanine cleaving amino-dipeptidases, specifically removes the two N-terminal amino acids from proteins having proline or alanine in position 2.
- DPP-IV DPP-IV
- DPP-IV has been implicated in the control of glucose metabolism because its substrates include the insulinotropic hormones Glucagon like peptide-1 (GLP-1) and Gastric inhibitory peptide (GIP). GLP-1 and GIP are active only in their intact forms; removal of their two N-terminal amino acids inactivates them.
- GLP-1 and GIP are active only in their intact forms; removal of their two N-terminal amino acids inactivates them.
- Diabetic dyslipidemia is characterized by multiple lipoprotein defects, including moderately high serum levels of cholesterol and triglycerides, small LDL particles, and low levels of HDL cholesterol.
- the results of recent clinical trials reveal beneficial effects of cholesterol-lowering therapy in diabetic and non-diabetic patients, thus supporting increased emphasis on treatment of diabetic dyslipidemia.
- the National Cholesterol Education Program's Adult Treatment Panel II advocated this need for intensive treatment of diabetic dyslipidemia.
- Obesity is a well-known risk factor for the development of many very common diseases such as atherosclerosis, hypertension and diabetes. The incidence of obese people and thereby also these diseases is increasing throughout the entire industrialised world.
- Such compounds have e.g. been disclosed in WO 98/19998, WO 00/34241, U.S. Pat. No. 6,124,305 (Novartis AG) and WO 99/38501 ( shareholders of Tufts University).
- the compounds of the present invention constitutes a completely novel class of DPP-IV inhibitors, structurally unrelated to any DPP-IV inhibitors known so far. They are furthermore potent and stable and thus offers a solution to the problems associated with the presently known DPP-IV inhibitors.
- each n is one or two independently
- R 1 is C ⁇ O; C ⁇ S; C 1 -C 2 alkyl optionally substituted with one or more R 4 independently; C 2 alkenyl substituted with one or more R 4 independently; C 2 alkynyl; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; perhalo C 1 -C 10 alkyl; perhalo C 1 -C 10 alkyloxy;
- R 2 is H; C 1 -C 7 alkyl optionally substituted with one or more R 4 independently; C 2 -C 7 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 7 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently, —SH; —SR 5 ; SOR 5 ; SO 2 R 5 ; —CHO; —CH(OR 5 ) 2 ; carboxy; —CO 2 R 4 ; NHCONNH
- R 3 is H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently; C 1 -C 10 alkyl-NH(CH 2 ) 1-4 NH-aryl optionally substituted with one or more R 4 independently; C 1 -C 10 alkyl-NH(CH 2 )
- R 4 is C 1 -C 10 alkyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 8 independently; aryl optionally substituted with one or more R 8 independently; heteroaryl optionally substituted with one or more R 8 independently; amino; amino substituted with one or more C 1 -C 10 alkyl optionally substituted with one or more R 8 ; amino substituted with one or two aryl optionally substituted with one or more R 8 independently; heteroaryl optionally substituted with one or more R 8 independently; ⁇ O; ⁇ S; —CO—R5; —COOR5; —O—CO-(C 1 -C 5
- R 5 is C 1 -C 10 alkyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 8 independently; aryl optionally substituted with one or more R 8 independently; aryl C 1 -C 5 alkyl optionally substituted with one or more R 8 independently; heteroaryl optionally substituted with one or more R 8 independently; heteroaryl C 1 -C 5 alkyl optionally substituted with one or more R 8 independently;
- R 6 is H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently;
- R 7 is H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently;
- R 8 is H, amidoxime; nitro, tetrazole; pentafluorophenyl; —CH 2 OH; —CHO; —C(OCH 3 ) 2 ; —COCH 3 ; —CF 3 ; —CCl 3 ; —OCF 3 ; —OCH 3 ; —CN; —CO 2 H; —CO 2 CH 3 ; —CONH 2 ; —CSNH 2 ; —CON 2 H 3 ; —SO 3 H; —SO 2 NH 2 ; —SO 2 NHCH 3 ; —SO 2 N(CH 3 ) 2 ; —SO 2 (1-piperazinyl);—SO 2 (4-methylpiperazin-1-yl); —SO 2 (pyrrolidin-1-yl); —SO 2 (piperidin-1-yl); —SO 2 (morpholin-4-yl); N-hydroxyimino; —NH 2 ; —NHCH 3 ; —NHCH 3
- R 9 is H; halogen; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently
- R 10 is H; halogen;
- R 9 and R 10 may be connected to form a cyclopropyl ring
- Compounds of formula I may be used for the manufacture of a medicament for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV.
- the invention relates to the use of compounds of formula II
- a 1 is a carbon or nitrogen atom
- the A-ring may be substituted with one or more R 3
- B 1 and B 2 are carbon or nitrogen atoms, independently,
- each B 3 is a carbon, nitrogen, oxygen, or sulfur atom, independently, each n 1 , n 2 , n 3 , n 4 is one or two, independently,
- D 3 , D 4 , and D 5 may be absent, in which case D 1 and D 2 may each be optionally substituted with one or two R 2 , independently,
- D 1 , D 2 , D 3 , D 4 , and each D 5 may independently be a carbon, nitrogen, oxygen, or a sulfur atom, or C ⁇ O, or C ⁇ S;
- the bonds in the B-ring may be saturated or unsaturated, such that the B-ring may be a five-membered or a six-membered carbocyclic or heterocyclic ring, which may be fully saturated, or partially or fully unsaturated;
- the bonds in the D-ring when present, may be saturated or unsaturated, such that the D-ring may be a five-membered or a six-membered carbocyclic or heterocyclic ring, which may be fully saturated, or partially or fully unsaturated;
- R 1 is C ⁇ O; C ⁇ S; C 1 -C 2 alkyl optionally substituted with one or more R 4 independently; C 2 alkenyl substituted with one or more R 4 independently; C 2 alkynyl; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; perhalo C 1 -C 10 alkyl; perhalo C 1 -C 10 alkyloxy;
- Each R 2 is independently H; C 1 -C 7 alkyl optionally substituted with one or more R 4 independently; C 2 -C 7 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 7 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently, —SH; —SR 5 ; SOR 5 ; SO 2 R 5 ; —CHO; —CH(OR 5 ) 2 ; carboxy; —CO 2 R 4 ; NH
- R 3 is H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 2 -C 6 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently; C 1 -C 10 alkyl-NH(CH 2 ) 1-4 NH-aryl optionally substituted with one or more R 4 independently; C 1 -C 10 alkyl-NH(CH 2 )
- R 4 is C 1 -C 10 alkyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 8 independently; C 2 -C 6 cycloheteroalkyl optionally substituted with one or more R 8 independently; aryl optionally substituted with one or more R 8 independently; heteroaryl optionally substituted with one or more R 8 independently; amino; amino substituted with one or more C 1 -C 10 alkyl optionally substituted with one or more R 8 ; amino substituted with one or two aryl optionally substituted with one or more R 8 independently; heteroaryl optionally substituted with one or more R 8 independently; ⁇ O; ⁇ S; —CO—R5; —COOR5; —O—CO-(C 1 -C 5
- R 5 is C 1 -C 10 alkyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 8 independently; aryl optionally substituted with one or more R 8 independently; aryl C 1 -C 5 alkyl optionally substituted with one or more R 8 independently; heteroaryl optionally substituted with one or more R 8 independently; heteroaryl C 1 -C 5 alkyl optionally substituted with one or more R 8 independently;
- R 8 is H, amidoxime; nitro, tetrazole; pentafluorophenyl; —CH2OH; —CHO; —C(OCH 3 ) 2 ; —COCH 3 ; —CF 3 ; —CCl 3 ; —OCF 3 ; —OCH 3 ; —CN; —CO 2 H; —CO 2 CH 3 ; —CONH 2 ; —CSNH 2 ; —CON 2 H 3 ; —SO 3 H; —SO 2 NH 2 ; —SO 2 NHCH 3 ; —SO 2 N(CH 3 ) 2 ; —SO 2 (1-piperazinyl);—SO 2 (-4-methylpiperazin-1-yl); —SO 2 (pyrrolidin-1-yl); —SO 2 (piperidin-1-yl); —SO 2 (morpholin-4-yl); N-hydroxyimino; —NH 2 ; —NHCH 3 ; —NHCH 3
- R 9 is H; halogen; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently
- R 10 is H; halogen;
- R9 and R10 may be connected to form a cyclopropyl ring
- DPP-IV Dipeptidyl peptidase IV (EC 3.4.14.5; DPP-IV), also known as CD26. DPP-IV cleaves a dipeptide from the N terminus of a polypeptide chain containing a proline or alanine residue in the penultimate position.
- treatment is defined as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or complications, or alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
- beta cell degeneration is intended to mean loss of beta cell function, beta cell dysfunction, and death of beta cells, such as necrosis or apoptosis of beta cells.
- C 1 -C 10 alkyl refers to a straight or branched, saturated hydrocarbon chain having from 1-10 carbon atoms such as but not limited to e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec. Butyl, isobutyl, tert. Butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 4-methylpentyl, neopentyl, 2,2-dimethylpropyl and the like.
- C 2 -C 10 -alkenyl used herein, alone or in combination, refers to a straight or branched, unsaturated hydrocarbon chain having from 2-10 carbon atoms and at least one double bond such as but not limited to vinyl, 1-propenyl, allyl, isopropenyl, n-butenyl, n-pentenyl and n-hexenyl and the like.
- C 2 -C 10 alkynyl refers to an unsaturated hydrocarbon chain having from 2-10 carbon atoms and at least one triple bond such as but not limited to —C ⁇ CH, —C ⁇ CCH 3 , —CH 2 C ⁇ CH, —CH 2 —CH 2 —C ⁇ CH, —CH(CH 3 ) C ⁇ CH and the like.
- C 1-10 -alkoxy as used herein, alone or in combination is intended to include those C 1-10 -alkyl groups of the designated length in either a linear or branched or cyclic configuration linked through an ether oxygen having its free valence bond from the ether oxygen.
- linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy.
- branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy and isohexoxy.
- cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.
- C 3 -C 10 cycloalkyl refers to a radical of one or more saturated cyclic hydrocarbon having from 3-10 carbon atoms such as but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl and the like.
- C 5 -C 10 cycloalkenyl refers to a radical of one or more cyclic hydrocarbon having at least one double bond having from 5-10 carbon atoms such as but not limited to cyclopentenyl, cyclohexenyl and the like
- C 2 -C 6 cycloheteroalkyl refers to a radical of totally saturated heterocycle like a cyclic hydrocarbon containing one or more heteroatoms selected from nitrogen, oxygen and sulphur independently in the cycle such as pyrrolidine (1-pyrrolidine; 2-pyrrolidine; 3-pyrrolidine; 4-pyrrolidine; 5-pyrrolidine); pyrazolidine (1-pyrazolidine; 2-pyrazolidine; 3-pyrazolidine; 4-pyrazolidine; 5-pyrazolidine); imidazolidine (1-imidazolidine; 2-imidazolidine; 3-imidazolidine; 4-imidazolidine; 5-imidazolidine); thiazolidine (2-thiazolidine; 3-thiazolidine; 4-thiazolidine; 5-thiazolidine); piperidine (1-piperidine; 2-piperidine; 3-piperidine; 4-piperidine; 5-piperidine; 6-piperidine); piperazine (1-piperazine; 2-piperazine;
- aryl as used herein includes carbocyclic aromatic ring systems. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems.
- heteroaryl as used herein includes heterocyclic unsaturated ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulphur such as furyl, thienyl, pyrrolyl, heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated below.
- aryl and “heteroaryl” as used herein refers to an aryl which can be optionally substituted or a heteroaryl which can be optionally substituted and includes phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N-hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1-anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (2-
- halogen refers to fluorine, chlorine, bromine or iodine.
- R 2 is preferably H; C 2 -C 7 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 7 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently, —SH; —SR 5 ; SOR 5 ; SO 2 R 5 ; —CHO; —CH(OR 5 ) 2 ; carboxy; —CO 2 R 4 ; NHCONNH 2 ; —NHCSNH 2 ;
- R 2 may be H; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently, —SH; —SR 5 ; SOR 5 ; SO 2 R 5 ; —CHO; —CH(OR 5 ) 2 ; carboxy; —CO 2 R 4 ; NHCONNH 2 ; —NHCSNH 2 ; —NHCONH 2 ; —NHCOR 4 ; —NHSO 2 R 5 ; —O—CO-(C 1 -C 5 ) alkyl optional
- R 2 may be H.
- R 1 may preferably be C ⁇ O; C ⁇ S; C 1 -C 2 alkyl substituted with one or more R 4 independently; C 2 alkenyl substituted with one or more R 4 independently; C 2 alkynyl; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl substituted with one or more R 4 independently; heteroaryl substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl substituted with one or more R 4 independently.
- R 9 is preferably H
- R 10 is preferably H
- R 6 and R 7 may independently be H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently.
- R 6 and R 7 may independently be H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently. More particularly, R 6 and R 7 may independently be H; C 1 -C 10 alkyl.
- R 6 and R 7 may independently be H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently.
- R 4 may be piperidino optionally substituted with one or more R 8 independently; piperazino optionally substituted with one or more R 8 independently; morpholino optionally substituted with one or more R 8 independently; thiomorpholino optionally substituted with one or more R 8 independently; pyrrolidino optionally substituted with one or more R 8 independently.
- R 6 and R 7 may independently be H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently.
- the invention provides compounds in one of the three groups A, B and C.
- n and m is one or two independently;
- R 1 is C ⁇ O; C ⁇ S; C 1 -C 2 alkyl; C 2 alkenyl; C 2 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl; heteroaryl-C 1 -C 3 alkyl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C 1 -C 3 alkyl, heteroaryl, or heteroaryl-C 1 -C 3 alkyl is optionally substituted with one or more R 4 independently;
- R 2 is H; C 1 -C 7 alkyl; C 2 -C 7 alkenyl; C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl-C 1 -C 3 alkyl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR 5 ; —SOR 5 ; —SO 2 R 5 ; carboxy; —CO 2 R 4 ; —CON(R 5 ) 2 ; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy, aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryloxy,
- R 3 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl-C 1 -C 3 alkyl; heteroaryl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; carboxy; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C 1 -C 3 alkyl, heteroaryl-C 1 -C 3 alkyl, heteroaryl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a
- R 4 , R 11 , R 12 , and R 17 are independently C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; trifluormethyl; N(R 13 ) 2 ; ⁇ O; ⁇ S; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy; aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R 8
- R 5 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 5 alkyl; heteroaryl; heteroaryl-C 1 -C 5 alkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl is optionally substituted with one or more R 14 independently;
- R 6 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 15 independently;
- R 7 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 16 independently;
- R 8 , R 14 , R 15 , and R 16 are independently H; nitro; —OCH 3 ; cyano; halogen; —OH; —SH; —SCH 3 ;
- R 9 is H; halogen; C 1 -C 10 alkyl or aryl, wherein alkyl or aryl is optionally substituted with one or more R 17 independently
- R 10 is H; halogen;
- R 9 and R 10 may be connected to form a cyclopropyl ring
- R 13 is H; C 1 -C 10 alkyl or aryl;
- n and m is one or two independently;
- R 1 is C ⁇ O; C ⁇ S; C 1 -C 2 alkyl; C 2 alkenyl; C 2 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl; heteroaryl-C 1 -C 3 alkyl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C 1 -C 3 alkyl, heteroaryl, or heteroaryl-C 1 -C 3 alkyl is optionally substituted with one or more R 4 independently;
- R 2 is H; C 1 -C 7 alkyl; C 2 -C 7 alkenyl; C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl-C 1 -C 3 alkyl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR 5 ; —SOR 5 ; —SO 2 R 5 ; carboxy; —CO 2 R 4 ; —CON(R 5 ) 2 ; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy, aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryloxy,
- R 3 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl-C 1 -C 3 alkyl; heteroaryl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; carboxy; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C 1 -C 3 alkyl, heteroaryl-C 1 -C 3 alkyl, heteroaryl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a
- R 4 , R 11 , R 12 , and R 17 are independently C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; trifluormethyl; N(R 13 ) 2 ; ⁇ O; ⁇ S; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy; aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R 8
- R 5 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 5 alkyl; heteroaryl; heteroaryl-C 1 -C 5 alkyl , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl is optionally substituted with one or more R 14 independently;
- R 6 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 15 independently;
- R 7 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 16 independently;
- R 8 , R 14 , R 15 , and R 16 are independently H; nitro; —OCH 3 ; cyano; halogen; —OH; —SH; —SCH 3 ;
- R 9 is H; halogen; C 1 -C 10 alkyl optionally substituted with one or more R 17 independently
- R 10 is H; halogen;
- R 9 and R 10 may be connected to form a cyclopropyl ring
- R 13 is H; C 1 -C 10 alkyl or aryl;
- n and m is one or two independently;
- R 1 is C ⁇ O; C ⁇ S; C 1 -C 2 alkyl; C 2 alkenyl; C 2 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl; heteroaryl-C 1 -C 3 alkyl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C 1 -C 3 alkyl, heteroaryl, or heteroaryl-C 1 -C 3 alkyl is optionally substituted with one or more R 4 independently;
- R 2 is H; C 1 -C 7 alkyl; C 2 -C 7 alkenyl; C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl-C 1 -C 3 alkyl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR 5 ; —SOR 5 ; —SO 2 R 5 ; carboxy; —CO 2 R 4 ; —CON(R 5 ) 2 ; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy, aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryloxy,
- R 3 is C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl-C 1 -C 3 alkyl; heteroaryl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; carboxy; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C 1 -C 3 alkyl, heteroaryl-C 1 -C 3 alkyl, heteroaryl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spir
- R 4 , R 11 , R 12 , and R 17 are independently C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; trifluormethyl; N(R 13 ) 2 ; ⁇ O; ⁇ S; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy; aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R 8
- R 5 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 5 alkyl; heteroaryl; heteroaryl-C 1 -C 5 alkyl , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl is optionally substituted with one or more R 14 independently;
- R 6 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 15 independently;
- R 7 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 16 independently;
- R 8 , R 14 , R 15 , and R 16 are independently H; nitro; —OCH 3 ; cyano; halogen; —OH; —SH; —SCH 3 ;
- R 9 is H; halogen; C 1 -C 10 alkyl optionally substituted with one or more R 17 independently
- R 10 is H; halogen;
- R 9 and R 10 may be connected to form a cyclopropyl ring
- R 13 is H; C 1 -C 10 alkyl or aryl;
- R 1 is C ⁇ O; C 1 -C 2 alkyl; C 2 alkenyl; C 2 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; or heteroaryl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 4 independently.
- R 1 is C ⁇ O; C 1 -C 2 alkyl; C 3 -C 7 cycloalkyl; aryl; or heteroaryl, wherein each alkyl, cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R 4 independently.
- R 1 is C ⁇ O or aryl optionally substituted with one or more R 4 independently.
- R 1 is aryl optionally substituted with one or more R 4 independently.
- R 1 is aryl
- R 1 is phenyl
- R 2 is H; C 1 -C 7 alkyl; C 2 -C 7 alkenyl; C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR 5 ; —SOR 5 ; —SO 2 R 5 ; —CO 2 R 4 ; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy, alkenyloxy, or alkynyloxy is optionally substituted with one or more R 11 independently.
- R 2 is H; C 1 -C 7 alkyl; C 3 -C 7 cycloheteroalkyl; aryl; cyano; halogen; nitro; —SR 5 ; —SO 2 R 5 ; —CO 2 R 4 ; or C 1 -C 10 alkyloxy; wherein each alkyl, cycloheteroalkyl, aryl, or alkyloxy is optionally substituted with one or more R 11 independently.
- R 2 is H; C 1 -C 7 alkyl; C 3 -C 7 cycloheteroalkyl; aryl; cyano; halogen; —CO 2 R 4 ; or C 1 -C 10 alkyloxy; wherein each alkyl, cycloheteroalkyl, aryl, or alkyloxy is optionally substituted with one or more R 11 independently.
- R 2 is H; C 1 -C 7 alkyl; cyano; halogen; or C 1 -C 10 alkyloxy; wherein each alkyl or alkyloxy is optionally substituted with one or more R 11 independently.
- R 2 is H; cyano or halogen.
- R 3 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; aryl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spiro system.
- R 3 is H; C 1 -C 10 alkyl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; hydroxy; wherein alkyl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spiro system.
- R 3 is H or C 1 -C 10 alkyl optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spiro system.
- R 3 is H or C 1 -C 10 alkyl.
- R 3 is methyl, ethyl, or isopropyl.
- R 3 is H.
- R 3 is C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; aryl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spiro system.
- R 3 is C 1 -C 10 alkyl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; hydroxy; wherein alkyl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spiro system.
- R 3 is C 1 -C 10 alkyl optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spiro system.
- R 3 is C 1 -C 10 alkyl.
- R 3 is methyl, ethyl, or isopropyl
- R 4 is C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R 8 independently.
- R 4 is C 1 -C 10 alkyl; C 2 -C 10 alkenyl; or C 2 -C 10 alkynyl; wherein each alkyl, alkenyl, or alkynyl is optionally substituted with one or more R 8 independently.
- R 4 is C 1 -C 10 alkyl optionally substituted with one or more R 8 independently.
- R 4 is C 1 -C 10 alkyl.
- R 4 is methyl
- R 5 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; aryl; heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R 14 independently.
- R 5 is C 1 -C 10 alkyl or aryl; wherein each alkyl or aryl is optionally substituted with one or more R 14 independently.
- R 6 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; or aryl; wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, or aryl is optionally substituted with one or more R 15 independently.
- R 6 is H; C 1 -C 10 alkyl; or C 2 -C 10 alkenyl; wherein each each alkyl or alkenyl is optionally substituted with one or more R 15 independently.
- R 6 is H or C 1 -C 10 alkyl optionally substituted with one or more R 15 independently.
- R 6 is H.
- R 6 is C 1 -C 10 alkyl optionally substituted with one or more R 15 independently.
- R 6 is C 1 -C 10 alkyl.
- R 6 is methyl
- R 7 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; or C 2 -C 10 alkynyl, wherein each each alkyl, alkenyl, or alkynyl is optionally substituted with one or more R 16 independently.
- R 7 is C 1 -C 10 alkyl optionally substituted with one or more R 16 independently.
- R 7 is C 1 -C 10 alkyl.
- R 8 is —OCH 3 .
- R 9 is aryl
- R 11 is C 1 -C 10 alkyl; aryl; cyano; halogen; wherein each alkyl or aryl is optionally substituted with one or more R 8 independently.
- R 11 is halogen
- R 12 is C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; wherein each alkyl, alkenyl, alkynyl, aryl, heteroaryl is optionally substituted with one or more R 8 independently.
- R 12 is aryl; heteroaryl; or hydroxy; wherein each aryl and heteroaryl is optionally substituted with one or more R 8 independently.
- R 12 is phenyl, pyridyl, or pyrrolidinyl.
- R 12 is hydroxy
- R 14 is halogen
- a further aspect of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising, as an active ingredient, at least one compound of the invention or a pharmaceutically acceptable salt or prodrug or hydrate thereof together with a pharmaceutically acceptable carrier or diluent.
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV.
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of metabolic disorders.
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for blood glucose lowering.
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of Type 2 diabetes.
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of impaired glucose tolerance (IGT).
- ITT impaired glucose tolerance
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of impaired fasting glucose (IFG).
- IGF impaired fasting glucose
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for prevention of hyperglycemia.
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for delaying the progression of impaired glucose tolerance (IGT) to Type 2 diabetes.
- ITT impaired glucose tolerance
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for delaying the progression of non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for increasing the number and/or the size of beta cells in a mammalian subject.
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of beta cell degeneration, in particular apoptosis of beta cells.
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of disorders of food intake.
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of obesity.
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for appetite regulation or induction of satiety.
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of dyslipidemia.
- a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of functional dyspepsia, in particular irritable bowel syndrome.
- a further aspect of the invention is a method for the treatment of diseases or disorders associated with proteins that are subject to inactivation by DPP-IV, the method comprising administering to a subject in need thereof an effective amount of a compound of the invention.
- a further aspect of the invention is methods of treating the above mentioned diseases, the method comprising administering to a subject in need thereof an effective amount of a compound of the invention.
- the compounds of the present invention may be prepared in the form of pharmaceutically acceptable salts, especially acid-addition salts, including salts of organic acids and mineral acids.
- salts include salts of organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid and the like.
- Suitable inorganic acid-addition salts include salts of hydrochloric, hydrobromic, sulphuric and phosphoric acids and the like.
- Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are known to the skilled artisan.
- the acid addition salts may be obtained as the direct products of compound synthesis.
- the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
- the compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
- the bonds in the B-ring may be unsaturated, such that the B-ring is a five-membered or a six-membered carbocyclic or heterocyclic ring, which is fully unsaturated.
- D 3 , D 4 and at least one D 5 are present, and D 1 , D 2 , D 3 , D 4 , and each D 5 may independently be a carbon, nitrogen, oxygen, or a sulfur atom, or C ⁇ O, or C ⁇ S, and the bonds in the B-ring are unsaturated, such that the B-ring is a five-membered or a six-membered carbocyclic or heterocyclic ring, which is fully unsaturated.
- the bonds in the D-ring are preferably unsaturated, such that the D-ring may be a five-membered or a six-membered carbocyclic or heterocyclic ring, which is fully unsaturated.
- each n 1 , n 2 may be one or two, independently n 3 is one, and n 4 is two,
- D 1 and D 2 may be carbon atoms
- D 4 and one of the D 5 may be nitrogen atoms
- D 3 and the other D 5 may be C ⁇ O, or C ⁇ S
- the bonds in the B-ring may be unsaturated, such that the B-ring is a five-membered carbocyclic or heterocyclic ring, which is fully unsaturated.
- n 1 is two and each of n 2 , n 3 , n 4 is one or two, independently.
- the B-ring is a benzene ring
- each n 1 , n 2 is one or two, independently,
- D 3 , D 4 , and D 5 are absent, such that D 1 and D 2 may each be optionally substituted with one R 2 , independently.
- the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one compound of the invention which inhibits the enzymatic activity of DPP-IV or a pharmaceutically acceptable salt or prodrug or hydrate thereof together with a pharmaceutically acceptable carrier or diluent.
- Pharmaceutical compositions containing a compound of the invention of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practise of Pharmacy, 19 th Ed., 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
- compositions include a compound of the invention which inhibits the enzymatic activity of DPP-IV or a pharmaceutically acceptable basic addition salt or prodrug or hydrate thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
- a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
- the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container.
- the carrier When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound.
- the active compound can be adsorbed on a granular solid container for example in a sachet.
- suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatine, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone.
- the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
- the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents.
- the formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
- compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds.
- the route of administration may be any route, which effectively transports the active compound of the invention which inhibits the enzymatic activity of DPP-IV to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
- the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
- the preparation may contain a compound of the invention which inhibits the enzymatic activity of DPP-IV, dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application.
- a liquid carrier in particular an aqueous carrier
- the carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
- injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
- Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
- Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch.
- a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
- a typical tablet which may be prepared by conventional tabletting techniques may contain:
- Core Core Active compound (as free compound or salt thereof) 250 mg Colloidal silicon dioxide (Aerosil) ® 1.5 mg Cellulose, microcryst. (Avicel) ® 70 mg Modified cellulose gum (Ac-Di-Sol) ® 7.5 mg Magnesium stearate Ad. Coating: HPMC approx. 9 mg *Mywacett 9-40 T approx. 0.9 mg
- the compounds of formula I and formula II may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of the various diseases as mentioned above, e.g. metabolic disorders, Type 2 diabetes, hyperglycemia, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), beta cell degeneration, apoptosis of beta cells, disorders of food intake, obesity, dyslipidemia, and functional dyspepsia, in particular irritable bowel syndrome.
- the compounds of formula I or formula II are contemplated to be useful for the prevention or treatment of Type 2 diabetes.
- the compounds of formula I or formula II may be useful for blood glucose lowering, prevention of hyperglycemia, delaying the progression of impaired glucose tolerance to Type 2 diabetes, delaying the progression of non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes, increasing the number and/or size of beta cells in a mammalian subject, or appetite regulation or induction of satiety.
- the mammal to be treated with a compound of formula I or formula II is preferably a human, but may also be an animal, both a domesticated animal, e.g. household pet, and non-domesticated animal such as wildlife.
- the compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, per day may be used. A most preferable dosage is about 0.5 mg to about 250 mg per day. In choosing a regimen for patients it may frequently be necessary to begin with a higher dosage and when the condition is under control to reduce the dosage. The exact dosage will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.
- the compounds of the present invention are dispensed in unit dosage form comprising from about 0.05 to about 1000 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
- dosage forms suitable for oral, nasal, pulmonal or transdermal administration comprise from about 0.05 mg to about 1000 mg, preferably from about 0.5 mg to about 250 mg of the compounds admixed with a pharmaceutically acceptable carrier or diluent.
- the invention also encompasses prodrugs of a compound of the invention which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances.
- prodrugs will be functional derivatives of a compound of the invention which are readily convertible in vivo into a compound af the invention.
- Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
- the invention also encompasses active metabolites of a compound of the invention.
- the preparation of the compounds of formula I can be done in many ways.
- the starting materials are either known compounds or compounds which may be prepared in analogy with the preparation of similar known compounds.
- a particularly useful synthesis is outlined below.
- the invention furthermore relates to the use of a compound according to the present invention for the preparation of a medicament for use in the treatment of diabetes in a regimen which additionally comprises treatment with another antidiabetic agent.
- insulinidiabetic agent includes compounds for the treatment and/or prophylaxis of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism.
- the antidiabetic agent is insulin or GLP-1 or any analogue or derivative thereof.
- the antidiabetic agent is a hypoglycaemic agent, preferably an oral hypoglycaemic agent.
- Oral hypoglycaemic agents are preferably selected from the group consisting of sulfonylureas, non-sulphonylurea insulin secretagogues, biguanides, thiazolidinediones, alpha glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, potasium channel openers, insulin sensitizers, hepatic enzyme inhibitors, glucose uptake modulators, compounds modifying the lipid metabolism, compounds lowering food intake, and agents acting on the ATP-dependent potassium channel of the 1-cells.
- sulfonylureas tolbutamide, glibenclamide, glipizide and gliclazide are preferred.
- repaglinide and nateglinide are preferred.
- metformin is preferred.
- troglitazone rosiglitazone and ciglitazone are preferred.
- acarbose is preferred.
- glibenclamide glipizide
- gliclazide gliclazide
- repaglinide a group consisting of glibenclamide, glipizide, gliclazide, repaglinide.
- CD26/DPP-IV Chemical compounds are tested for their ability to inhibit the enzyme activity of purified CD26/DPP-IV. Briefly, the activity of CD26/DPP-IV is measured in vitro by its ability to cleave the synthetic substrate Gly-Pro-p-nitroanilide (Gly-Pro-pNA). Cleavage of Gly-Pro-pNA by DPP-IV liberates the product p-nitroanilide (pNA), whose rate of appearance is directly proportional to the enzyme activity. Inhibition of the enzyme activity by specific enzyme inhibitors slows down the generation of pNA. Stronger interaction between an inhibitor and the enzyme results in a slower rate of generation of pNA.
- Gly-Pro-pNA Gly-Pro-pNA
- the degree of inhibition of the rate of accumulation of pNA is a direct measure of the strength of enzyme inhibition.
- the accumulation of pNA is measured spectrophotometrically.
- the inhibition constant, Ki, for each compound is determined by incubating fixed amounts of enzyme with several different concentrations of inhibitor and substrate.
- Assay buffer 50 mM Tris pH7.4, 150 mM NaCl, 0.1% Triton X-100.
- the Zucker Diabetic Fatty (ZDF) rat model can be used to investigate the effects of the compounds of the invention on both the treatment and prevention of diabetes as rats of this sub-strain are initially pre-diabetic although develop severe type 2 diabetes characterised by increased HbA1c levels over a period of 6 weeks.
- the same strain can be used to predict the clinical efficacy of other anti-diabetic drug types.
- the model predicts the potency and limited clinical efficacy of thiazolidinedione insulin sensitiser compounds.
- a Valco column switch with a Valco actuator controlled by timed events from the pump is a Valco column switch with a Valco actuator controlled by timed events from the pump.
- HPLC pump was connected to four eluent reservoirs containing:
- samples contain approximately 500 ⁇ g/ml of the compound to be analysed in an acceptable solvent such as methanol, ethanol, acetonitrile, THF, water and mixtures thereof. (High concentrations of strongly eluting solvents will interfere with the chromatography at low acetonitrile concentrations.)
- an acceptable solvent such as methanol, ethanol, acetonitrile, THF, water and mixtures thereof.
- the detection data were acquired concurrently from the mass spectrometer, the UV detector and the ELS detector.
- Step B Preparation of (2-Amino-propionylamino) Acetic Acid Methyl Ester Derivatives
- Step E and F are described in J.Org.Chem. 50 (24); 1985; 4796-4799 while step D is as described above.
- Step E Preparation of t-Boc-dipeptide Esters
- the ethyl acetate phase is decanted to a new scintillations vessel.
- the water/DMF-phase is then extracted with DCM (5 ml).
- the DCM and ethyl acetate phase are combined and evaporated in a speedvac. The residue is used without any purification in the next step.
- R 1 , R 3 , R 6 , R 7 , X and n are defined as in formula I.
- Alkylation reagent R 6 -X (32 ⁇ mol) is dissolved in DMF (100 ⁇ l) and added to the above reaction mixture, followed by a solution of TMG in DMF (1.16 ml TMG diluted to 5.8 ml, 48 ul). The mixture is kept at 65° C. for 4 h.
- the first reaction step is identical to Step A in general procedure (A)
- the first reaction step is identical to Step A in general procedure (A)
- 1,4-Dibenzyl-[1,4]diazepane-5,7-dione is converted to the Na-salt in THF with NaH as base, and reacted with the R 3 —X alkylating reagent e.g. benzyl bromide, at room temperature.
- the product e.g. 1,4,6-Tribenzyl-[1,4]diazepane-5,7-dione is reduced to the 1,4,6-Tribenzyl-[1,4]diazepane by treatment with LiAlH4 in THF at elevated temperature.
- the N-benzyl groups are removed by catalytic hydrogenation in EtOH:AcOH (1:1), using Pd/C as catalyst.
- Step A Preparation of 1,4-dibenzyl-[1,4]diazepane-6-carboxylic Acid. Na-salt (1A)
- N,N′-dibenzylethylenediamine (4.9 ml, 20.8 mmol) was dissolved in toluene (200 ml), triethylamine (8.94 ml, 64.5 mmol), and methanol (20 ml) and 3-bromo-2-bromomethylpropionic acid (5.12 g, 20.8 mmol) was added.
- the reaction mixture was heated to reflux for 24 hours. The solvents were evaporated and the remaining was redissolved in water (150 ml) and ethyl acetate (150 ml).
- the aqueous layer was washed with 4 ⁇ 150 ml of ethyl acetate, and then evaporated to dryness. The remaining was suspended in ethyl acetate (200 ml) and dry methanol (20 ml) and salts was filtered off.
- the mother liquor was evaporated and purified by chromatography on silica, using 10% methanol in dichloromethane as the eluent. Fractions containing the product were evaporated, to afford 5.09 g of 1A as an yellow foam in 70% yield.
- Step B Preparation of (1,4-dibenzyl-[1,4]diazepan-6-yl)methanol (1B)
- Step D Preparation of 7-benzyl-8-(6-hydroxymethyl-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione.
- Step A Preparation of 1,4-dibenzyl-[1,4]diazepan-6-ol (2A)
- N,N′-dibenzylethylenediamine (4.9 ml, 20.8 mmol) was dissolved in toluene (200 ml), triethylamine (8.94 ml, 64.5 mmol), and 1,3-dibromo-2-propanol (4.53 g, 20.8 mmol) was added.
- the reaction mixture was heated to reflux for 4 days.
- the solvents were evaporated and the remaining was redissolved in water (150 ml) and ethyl acetate (150 ml).
- Step C Preparation of 7-Benzyl-8-(6-hydroxy-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione.
- the aqueous layer was extracted with 3 ⁇ 50 ml of dichloromethane, and the combined organic material were added excess trifluoroacetic acid, and evaporated, to afford 123 mg of the title compound as a brown oil in 75% yield.
- Step A Preparation of 1,4-dibenzyl-[1,4]diazepane-2-carboxylic Acid Methyl Ester (3A)
- N,N′-Dibenzylpropane-1,3-diamine (Sandstroem, J. et al, Tetrahedron; EN; 34; 1978; 371-378) (2.0 g, 7.86 mmol), methyl 2,3-dibromopropionate (1.28 ml, 7.86 mmol), and potassium carbonate (2.17 g, 15.72 mmol) were dissolved in dry dimethylformamide (125 ml) and methanol (20 ml) and the mixture was heated to reflux for 6 days. The reaction mixture was allowed to cool to room temperature and water (200 ml) and ethyl acetate (200 ml) were added.
- the aqueous layer was extracted with 2 ⁇ 200 ml of ethyl acetate, and the combined organic layers were dried with sodium sulfate, filtered and the solvent was evaporated.
- the crude product was purified by chromatography on silica, using a mixture of ethyl acetate and heptane 1:6 as the eluent. Fractions containing the product were evaporated, to afford 180 mg of 3A as an clear oil in 7% yield.
- Step B Preparation of (1,4-dibenzyl-[1,4]diazepan-2-yl)-methanol (3B)
- Step D Preparation of 7-benzyl-8-(3-hydroxymethyl-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione.
- Step A Preparation of 7-benzyl-8-chloro-1,3-dimethyl-3,7-dihydro-purine-2,6-dione (4A)
- Step B Preparation of 4-(7-Benzyl-1,3-dimethyl-2,6-dioxo-2,3,4,5-tetrahydro-1H-purine-8-yl)-piperazine-1-carboxylic acid tert-butylate (4B)
- Step C Preparation of 4-(7-Benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione.
- DMSO d6 d 10.90 (s, 1H); 8.65 (s br, 2H); 7.40-7.20 (m, 8H); 7.14 (d, 2H); 5.43 (s, 2H); 5.06 (s, 2H); 3.65 (m, 2H); 3.48 (m, 2H); 3.26 (m, 2H); 3.16 (s br, 2H); 1.97 (m, 2H)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/935,149 US20020161001A1 (en) | 2000-07-04 | 2001-08-22 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV |
US10/621,302 US7235538B2 (en) | 2000-07-04 | 2003-07-17 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200001040 | 2000-07-04 | ||
DKPA200001040 | 2000-07-04 | ||
US22324000P | 2000-08-04 | 2000-08-04 | |
PCT/DK2001/000467 WO2002002560A2 (en) | 2000-07-04 | 2001-07-04 | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
US09/935,149 US20020161001A1 (en) | 2000-07-04 | 2001-08-22 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2001/000467 Continuation WO2002002560A2 (en) | 2000-07-04 | 2001-07-04 | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/621,302 Continuation US7235538B2 (en) | 2000-07-04 | 2003-07-17 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020161001A1 true US20020161001A1 (en) | 2002-10-31 |
Family
ID=26068848
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/935,149 Abandoned US20020161001A1 (en) | 2000-07-04 | 2001-08-22 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV |
US10/621,302 Expired - Fee Related US7235538B2 (en) | 2000-07-04 | 2003-07-17 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/621,302 Expired - Fee Related US7235538B2 (en) | 2000-07-04 | 2003-07-17 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV |
Country Status (8)
Country | Link |
---|---|
US (2) | US20020161001A1 (xx) |
EP (1) | EP1301187B1 (xx) |
JP (1) | JP2004502690A (xx) |
AU (2) | AU2001268958B2 (xx) |
HU (1) | HUP0301622A3 (xx) |
MX (1) | MXPA02012272A (xx) |
PL (1) | PL360856A1 (xx) |
WO (1) | WO2002002560A2 (xx) |
Cited By (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030199528A1 (en) * | 2001-09-19 | 2003-10-23 | Kanstrup Anders B. | Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV |
US20030232987A1 (en) * | 2002-05-31 | 2003-12-18 | Schering Corporation | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof |
WO2003104229A1 (ja) | 2002-06-06 | 2003-12-18 | エーザイ株式会社 | 新規縮合イミダゾール誘導体 |
US20040077645A1 (en) * | 2001-02-24 | 2004-04-22 | Frank Himmelsbach | Xanthine derivatives,production and use thereof as medicament |
US20040097510A1 (en) * | 2002-08-21 | 2004-05-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20040138215A1 (en) * | 2002-11-21 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040138214A1 (en) * | 2002-11-08 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040152745A1 (en) * | 1999-11-12 | 2004-08-05 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors |
US20040166125A1 (en) * | 2002-08-22 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
US20050187227A1 (en) * | 2004-02-23 | 2005-08-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition |
US20050203095A1 (en) * | 2004-03-13 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US20050234108A1 (en) * | 2004-02-18 | 2005-10-20 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US20050261352A1 (en) * | 2004-05-10 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US20060004074A1 (en) * | 2004-06-24 | 2006-01-05 | Boehringer Ingelheim International Gmbh | New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US20060058323A1 (en) * | 2004-09-11 | 2006-03-16 | Boehringer Ingelheim International Gmbh | New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20060079541A1 (en) * | 2004-09-14 | 2006-04-13 | Boehringer Ingelheim International Gmbh | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20060142310A1 (en) * | 2004-11-05 | 2006-06-29 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines |
US7074798B2 (en) | 2002-02-25 | 2006-07-11 | Eisai Co., Ltd | Xanthine derivative and DPPIV inhibitor |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20070027168A1 (en) * | 2005-07-30 | 2007-02-01 | Waldemar Pfrengle | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US20070082908A1 (en) * | 2003-08-29 | 2007-04-12 | Dainippon Sumitomo Pharma Co., Ltd. | Bicycle pyrazole derivative |
US20070219178A1 (en) * | 2003-12-04 | 2007-09-20 | Eisai Co., Ltd. | Preventive or therapeutic agents for multiple sclerosis |
US20070259900A1 (en) * | 2006-05-04 | 2007-11-08 | Peter Sieger | Polymorphs |
US20070281940A1 (en) * | 2006-05-04 | 2007-12-06 | Klaus Dugi | Uses of dpp-iv inhibitors |
US20080107731A1 (en) * | 2006-05-04 | 2008-05-08 | Anja Kohlrausch | Dpp iv inhibitor formulations |
US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
US20090088569A1 (en) * | 2004-04-10 | 2009-04-02 | Matthias Eckhardt | 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation, and their use as pharmaceutical compositions |
US20090110647A1 (en) * | 2007-10-24 | 2009-04-30 | Peter Richardson | Method of preventing adverse effects by glp-1 |
US7550455B2 (en) | 2003-11-27 | 2009-06-23 | Boehringer Ingelheim International Gmbh | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition |
US7566707B2 (en) | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7569574B2 (en) | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2010080964A1 (en) * | 2009-01-08 | 2010-07-15 | Mannkind Corporation | Method for treating hyperglycemia with glp-1 |
WO2010079197A1 (en) * | 2009-01-07 | 2010-07-15 | Boehringer Ingelheim International Gmbh | Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor |
US7825242B2 (en) | 2004-07-16 | 2010-11-02 | Takeda Pharmaceutical Company Limted | Dipeptidyl peptidase inhibitors |
US20110092510A1 (en) * | 2008-06-03 | 2011-04-21 | Boehringer Ingelheim International Gmbh | Dpp-iv inhibitors for use in the treatment of nafld |
US20110112069A1 (en) * | 2007-08-17 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
US7960384B2 (en) | 2006-03-28 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20110190322A1 (en) * | 2008-08-14 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
US20110206766A1 (en) * | 2008-04-03 | 2011-08-25 | Boehringer Ingelheim International Gmbh | Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US8071583B2 (en) | 2006-08-08 | 2011-12-06 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US8853156B2 (en) | 2008-08-06 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US8921311B2 (en) | 2003-08-01 | 2014-12-30 | Mannkind Corporation | Method for treating hyperglycemia |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US9149478B2 (en) | 2010-06-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9192675B2 (en) | 2008-06-13 | 2015-11-24 | Mankind Corporation | Dry powder inhaler and system for drug delivery |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9486526B2 (en) | 2008-08-06 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
US9713618B2 (en) | 2012-05-24 | 2017-07-25 | Boehringer Ingelheim International Gmbh | Method for modifying food intake and regulating food preference with a DPP-4 inhibitor |
US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003000180A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
ATE318139T1 (de) | 2001-06-20 | 2006-03-15 | Merck & Co Inc | Dipeptidylpeptidase-hemmer zur behandlung von diabetes |
US7183290B2 (en) | 2001-06-27 | 2007-02-27 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
JP4300108B2 (ja) | 2001-06-27 | 2009-07-22 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのピロリジン類 |
CA2450722A1 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
EP1404675B1 (en) * | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
US6869947B2 (en) | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US20070197552A1 (en) * | 2002-01-11 | 2007-08-23 | Novo Nordisk A/S | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states |
WO2004009091A1 (en) | 2002-06-17 | 2004-01-29 | Glaxo Group Limited | Purine derivatives as liver x receptor agonists |
AU2003251869A1 (en) | 2002-07-15 | 2004-02-02 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
KR101150449B1 (ko) * | 2002-08-21 | 2012-06-01 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 8-[3-아미노-피페리딘-1-일]-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
DE10238470A1 (de) * | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10238477A1 (de) * | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
WO2004024184A1 (ja) * | 2002-09-11 | 2004-03-25 | Takeda Pharmaceutical Company Limited | 徐放性製剤 |
JPWO2004028524A1 (ja) * | 2002-09-26 | 2006-01-19 | エーザイ株式会社 | 併用医薬 |
US7390809B2 (en) | 2002-10-07 | 2008-06-24 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for diabetes |
AU2003269850A1 (en) * | 2002-10-08 | 2004-05-04 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
MXPA05004063A (es) | 2002-10-18 | 2005-06-08 | Merck & Co Inc | Inhibidores de la beta-amino heterociclico dipeptidil peptidasa para el tratamiento o prevencion de diabetes. |
AU2003280680A1 (en) * | 2002-11-01 | 2004-06-18 | Sumitomo Pharmaceuticals Co., Ltd. | Xanthine compound |
AU2003290577B2 (en) | 2002-11-07 | 2008-12-11 | Merck Sharp & Dohme Corp. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
DE10251927A1 (de) * | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US7109192B2 (en) | 2002-12-03 | 2006-09-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions |
UY28103A1 (es) * | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
WO2004064778A2 (en) | 2003-01-17 | 2004-08-05 | Merck & Co. Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004069162A2 (en) | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
JP4887139B2 (ja) * | 2003-03-25 | 2012-02-29 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
CN101837127A (zh) | 2003-05-05 | 2010-09-22 | 前体生物药物股份公司 | 谷氨酰胺酰基和谷氨酸环化酶效应物的应用 |
EP1620082B9 (en) | 2003-05-05 | 2010-08-25 | Probiodrug AG | Medical use of inhibitors of glutaminyl and glutamate cyclases for treating alzheimer's disease and down syndrome |
DE602004026289D1 (de) | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminylcyclase-hemmer |
EP1624874B1 (en) | 2003-05-14 | 2009-11-04 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
CN1798556A (zh) | 2003-06-06 | 2006-07-05 | 麦克公司 | 作为治疗或者预防糖尿病的二肽基肽酶抑制剂的稠合吲哚 |
CN1809544A (zh) | 2003-06-17 | 2006-07-26 | 麦克公司 | 作为二肽基肽酶抑制剂用于治疗或预防糖尿病的环己基甘氨酸衍生物 |
DE10327439A1 (de) * | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE602004018503D1 (de) | 2003-07-31 | 2009-01-29 | Merck & Co Inc | Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes |
RU2006107553A (ru) * | 2003-08-13 | 2007-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 4-пиримидона и их применение в качестве ингибиторов пептидилпептидаз |
EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20050065144A1 (en) * | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
WO2005039548A2 (en) | 2003-10-15 | 2005-05-06 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
ZA200603165B (en) | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
KR20180050427A (ko) | 2003-11-17 | 2018-05-14 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
US7217711B2 (en) | 2003-12-17 | 2007-05-15 | Boehringer Ingelheim International Gmbh | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions |
DE10359098A1 (de) * | 2003-12-17 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel |
RS57561B1 (sr) | 2004-01-20 | 2018-10-31 | Novartis Ag | Formulacija dobijena direktnom kompresijom i proces za njeno dobijanje |
AU2005210004B2 (en) | 2004-02-05 | 2010-10-28 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
PT1758905E (pt) | 2004-02-18 | 2009-07-16 | Boehringer Ingelheim Int | 8-[3-amino-piperidin-1-il]-xantinas, sua preparação e sua utilização como inibidores de dpp-iv |
NZ549716A (en) | 2004-03-15 | 2010-04-30 | Takeda Pharmaceutical | Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors |
US7687492B2 (en) | 2004-05-04 | 2010-03-30 | Merck Sharp & Dohme Corp. | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
US7671073B2 (en) | 2004-05-18 | 2010-03-02 | Merck Sharp & Dohme Corp. | Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
ATE553077T1 (de) * | 2004-07-23 | 2012-04-15 | Nuada Llc | Peptidaseinhibitoren |
DE102004038270A1 (de) * | 2004-08-06 | 2006-03-16 | Sanofi-Aventis Deutschland Gmbh | Substituierte, bizyklische 8-Amino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102004038268A1 (de) * | 2004-08-06 | 2006-03-16 | Sanofi-Aventis Deutschland Gmbh | Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
EP2602259A3 (en) | 2005-02-18 | 2014-09-10 | Mitsubishi Tanabe Pharma Corporation | Salt of proline derivative, solvate thereof, and production method thereof |
MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
FR2889189A1 (fr) * | 2005-07-28 | 2007-02-02 | Cerep Sa | Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1 |
PE20070458A1 (es) * | 2005-09-14 | 2007-07-05 | Takeda Pharmaceutical | Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa |
NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
KR100792275B1 (ko) * | 2006-02-22 | 2008-01-08 | 영진약품공업주식회사 | 베타아미노기를 갖는 고리화된 히드라자이드 유도체, 이의 약학적으로 허용 가능한 염 및 이의 제조 방법 |
EP1999108A1 (en) * | 2006-03-28 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
CL2007001011A1 (es) | 2006-04-11 | 2008-05-16 | Arena Pharm Inc | Metodo para la identificacion de secretagogos de gip, polipeptido inhibidor gastrico; y uso de un receptor acoplado a proteina g para clasificar compuestos de prueba como secretagogos de gip. |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
KR20090004950A (ko) | 2006-04-12 | 2009-01-12 | 프로비오드룩 아게 | 효소 억제제 |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
KR20090088854A (ko) * | 2006-09-13 | 2009-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도 |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
JP5685550B2 (ja) | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Sglt2阻害剤、dpp−iv阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
MX2012010470A (es) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5). |
BR112012025592A2 (pt) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
WO2015003881A1 (en) * | 2013-07-08 | 2015-01-15 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
WO2016207364A1 (en) * | 2015-06-25 | 2016-12-29 | Boehringer Ingelheim International Gmbh | Process for the preparation of a xanthine-based compound |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT313916B (de) | 1971-10-28 | 1974-03-11 | Degussa | Verfahren zur Herstellung von neuen basisch substituierten Theophyllinen und deren Säureadditionssalzen |
US4719245A (en) * | 1984-03-08 | 1988-01-12 | The Dow Chemical Company | Flexible polyisocyanurate-urethane foam |
US4636229A (en) * | 1984-03-26 | 1987-01-13 | Nippon Oil Company, Limited | Selective gas separation membrane |
FR2654935B1 (fr) * | 1989-11-28 | 1994-07-01 | Lvmh Rech | Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux. |
GB9020959D0 (en) * | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
FR2668150B1 (fr) * | 1990-10-17 | 1994-11-18 | Theramex | Nouveaux derives du terbutylphenyl 1-amino 4-hydroxybutane, leurs procedes de preparation et les compositions pharmaceutiques en renfermant. |
US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
EP1052994A2 (en) | 1998-02-02 | 2000-11-22 | Trustees Of Tufts College | Use of dipeptidylpetidase inhibitors to regulate glucose metabolism |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6815446B1 (en) * | 1999-08-31 | 2004-11-09 | Vanderbilt University | Selective antagonists of A2B adenosine receptors |
NZ528216A (en) * | 2001-02-24 | 2006-12-22 | Boehringer Ingelheim Pharma | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
AU2002359365B2 (en) * | 2001-11-09 | 2008-07-10 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
EP1338595B1 (en) * | 2002-02-25 | 2006-05-03 | Eisai Co., Ltd. | Xanthine derivatives as DPP-IV inhibitors |
PL374007A1 (en) * | 2002-06-06 | 2005-09-19 | Eisai Co, Ltd. | Novel fused imidazole derivative |
US7879316B2 (en) * | 2002-06-12 | 2011-02-01 | L'oreal | Cosmetic composition containing a polyorganosiloxane polymer |
FR2841346B1 (fr) * | 2002-06-19 | 2004-11-05 | Eastman Kodak Co | Procede de developpement d'un produit photographique a haut contraste contenant un agent de nucleation de type polyhydrazide |
-
2001
- 2001-07-04 HU HU0301622A patent/HUP0301622A3/hu unknown
- 2001-07-04 PL PL01360856A patent/PL360856A1/xx not_active Application Discontinuation
- 2001-07-04 JP JP2002507812A patent/JP2004502690A/ja not_active Withdrawn
- 2001-07-04 AU AU2001268958A patent/AU2001268958B2/en not_active Expired - Fee Related
- 2001-07-04 AU AU6895801A patent/AU6895801A/xx active Pending
- 2001-07-04 EP EP01947211A patent/EP1301187B1/en not_active Expired - Lifetime
- 2001-07-04 WO PCT/DK2001/000467 patent/WO2002002560A2/en not_active Application Discontinuation
- 2001-07-04 MX MXPA02012272A patent/MXPA02012272A/es active IP Right Grant
- 2001-08-22 US US09/935,149 patent/US20020161001A1/en not_active Abandoned
-
2003
- 2003-07-17 US US10/621,302 patent/US7235538B2/en not_active Expired - Fee Related
Cited By (189)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
US20040152745A1 (en) * | 1999-11-12 | 2004-08-05 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors |
US20110144095A1 (en) * | 2001-02-24 | 2011-06-16 | Boehringer Ingelheim Pharma & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040087587A1 (en) * | 2001-02-24 | 2004-05-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20100173916A1 (en) * | 2001-02-24 | 2010-07-08 | Boehringer Ingelheim International Gmbh | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions |
US20060247226A1 (en) * | 2001-02-24 | 2006-11-02 | Frank Himmelsbach | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040077645A1 (en) * | 2001-02-24 | 2004-04-22 | Frank Himmelsbach | Xanthine derivatives,production and use thereof as medicament |
US20110144083A1 (en) * | 2001-02-24 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions |
US20100204250A1 (en) * | 2001-02-24 | 2010-08-12 | Boehringer Ingelheim Pharma & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20030199528A1 (en) * | 2001-09-19 | 2003-10-23 | Kanstrup Anders B. | Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV |
US7074798B2 (en) | 2002-02-25 | 2006-07-11 | Eisai Co., Ltd | Xanthine derivative and DPPIV inhibitor |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US7074923B2 (en) * | 2002-05-31 | 2006-07-11 | Schering Corporation | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof |
US7786301B2 (en) * | 2002-05-31 | 2010-08-31 | Schering Corporation | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof |
US20030232987A1 (en) * | 2002-05-31 | 2003-12-18 | Schering Corporation | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof |
US20060205943A1 (en) * | 2002-05-31 | 2006-09-14 | Schering Corporation | Process for preparing xanthine phosphodiesterase V inhibitors and precursers thereof |
US7772226B2 (en) | 2002-06-06 | 2010-08-10 | Eisai R&D Management Co., Ltd. | Condensed imidazole derivatives |
US20090018331A1 (en) * | 2002-06-06 | 2009-01-15 | Eisai R&D Management Co., Ltd. | Condensed imidazole derivatives |
US20060063787A1 (en) * | 2002-06-06 | 2006-03-23 | Eisai Co., Ltd. | Condensed imidazole derivatives |
WO2003104229A1 (ja) | 2002-06-06 | 2003-12-18 | エーザイ株式会社 | 新規縮合イミダゾール誘導体 |
US20060100199A1 (en) * | 2002-06-06 | 2006-05-11 | Seiji Yoshikawa | Novel condensed imidazole derivatives |
US20040116328A1 (en) * | 2002-06-06 | 2004-06-17 | Eisai Co., Ltd. | Condensed imidazole derivatives |
US9108964B2 (en) | 2002-08-21 | 2015-08-18 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8119648B2 (en) | 2002-08-21 | 2012-02-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20040097510A1 (en) * | 2002-08-21 | 2004-05-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US10023574B2 (en) | 2002-08-21 | 2018-07-17 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9556175B2 (en) | 2002-08-21 | 2017-01-31 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions |
US20080255159A1 (en) * | 2002-08-21 | 2008-10-16 | Boehringer Ingelheim Pharma Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US10202383B2 (en) | 2002-08-21 | 2019-02-12 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8178541B2 (en) | 2002-08-21 | 2012-05-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9321791B2 (en) | 2002-08-21 | 2016-04-26 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8664232B2 (en) | 2002-08-21 | 2014-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20040166125A1 (en) * | 2002-08-22 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
US7495005B2 (en) | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
US7569574B2 (en) | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7838529B2 (en) | 2002-08-22 | 2010-11-23 | Boehringer Ingelheim International Gmbh | Xanthine derivates, their preparation and their use in pharmaceutical compositions |
US20090131432A1 (en) * | 2002-08-22 | 2009-05-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivates, their preparation and their use in pharmaceutical compositions |
US20100144703A1 (en) * | 2002-11-08 | 2010-06-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7696212B2 (en) | 2002-11-08 | 2010-04-13 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040138214A1 (en) * | 2002-11-08 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7560450B2 (en) | 2002-11-21 | 2009-07-14 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040138215A1 (en) * | 2002-11-21 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7566707B2 (en) | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US8034941B2 (en) | 2003-06-18 | 2011-10-11 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20090258856A1 (en) * | 2003-06-18 | 2009-10-15 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US8921311B2 (en) | 2003-08-01 | 2014-12-30 | Mannkind Corporation | Method for treating hyperglycemia |
US9078866B2 (en) | 2003-08-01 | 2015-07-14 | Mannkind Corporation | Method for treating hyperglycemia with GLP-1 |
US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20070082908A1 (en) * | 2003-08-29 | 2007-04-12 | Dainippon Sumitomo Pharma Co., Ltd. | Bicycle pyrazole derivative |
US7550455B2 (en) | 2003-11-27 | 2009-06-23 | Boehringer Ingelheim International Gmbh | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition |
US20070219178A1 (en) * | 2003-12-04 | 2007-09-20 | Eisai Co., Ltd. | Preventive or therapeutic agents for multiple sclerosis |
US20090137801A1 (en) * | 2004-02-18 | 2009-05-28 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US20050234108A1 (en) * | 2004-02-18 | 2005-10-20 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US8697868B2 (en) | 2004-02-18 | 2014-04-15 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US7645763B2 (en) | 2004-02-23 | 2010-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition |
US20050187227A1 (en) * | 2004-02-23 | 2005-08-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20050203095A1 (en) * | 2004-03-13 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US7393847B2 (en) | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US7432262B2 (en) | 2004-03-13 | 2008-10-07 | Boehringer Ingelheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US20090088569A1 (en) * | 2004-04-10 | 2009-04-02 | Matthias Eckhardt | 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation, and their use as pharmaceutical compositions |
US20050261352A1 (en) * | 2004-05-10 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US7439370B2 (en) | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US7667035B2 (en) | 2004-05-10 | 2010-02-23 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US20080312243A1 (en) * | 2004-06-24 | 2008-12-18 | Matthias Eckhardt | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US7470716B2 (en) | 2004-06-24 | 2008-12-30 | Boehringer Ingelheim International Gmbh | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US20060004074A1 (en) * | 2004-06-24 | 2006-01-05 | Boehringer Ingelheim International Gmbh | New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US7906539B2 (en) | 2004-06-24 | 2011-03-15 | Boehringer Ingelheim International Gmbh | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US7825242B2 (en) | 2004-07-16 | 2010-11-02 | Takeda Pharmaceutical Company Limted | Dipeptidyl peptidase inhibitors |
US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US10130685B2 (en) | 2004-08-23 | 2018-11-20 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US7495003B2 (en) | 2004-09-11 | 2009-02-24 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20060058323A1 (en) * | 2004-09-11 | 2006-03-16 | Boehringer Ingelheim International Gmbh | New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20060079541A1 (en) * | 2004-09-14 | 2006-04-13 | Boehringer Ingelheim International Gmbh | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7495002B2 (en) | 2004-09-14 | 2009-02-24 | Boehringer Ingelheim International Gmbh | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9499546B2 (en) | 2004-11-05 | 2016-11-22 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US9751855B2 (en) | 2004-11-05 | 2017-09-05 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US20060142310A1 (en) * | 2004-11-05 | 2006-06-29 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines |
US8883805B2 (en) | 2004-11-05 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US20090192314A1 (en) * | 2004-11-05 | 2009-07-30 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines |
US7820815B2 (en) | 2004-11-05 | 2010-10-26 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines |
US8541450B2 (en) | 2004-11-05 | 2013-09-24 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines |
US20070027168A1 (en) * | 2005-07-30 | 2007-02-01 | Waldemar Pfrengle | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US8106060B2 (en) | 2005-07-30 | 2012-01-31 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US8637530B2 (en) | 2005-07-30 | 2014-01-28 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US9446001B2 (en) | 2005-09-14 | 2016-09-20 | Mannkind Corporation | Increasing drug affinity for crystalline microparticle surfaces |
US9717689B2 (en) | 2005-09-14 | 2017-08-01 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US10143655B2 (en) | 2005-09-14 | 2018-12-04 | Mannkind Corporation | Method of drug formulation |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US10130581B2 (en) | 2006-02-22 | 2018-11-20 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US7960384B2 (en) | 2006-03-28 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8673927B2 (en) | 2006-05-04 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US9173859B2 (en) | 2006-05-04 | 2015-11-03 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US11919903B2 (en) | 2006-05-04 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Polymorphs |
US11291668B2 (en) | 2006-05-04 | 2022-04-05 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US11084819B2 (en) | 2006-05-04 | 2021-08-10 | Boehringer Ingelheim International Gmbh | Polymorphs |
US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
US8232281B2 (en) | 2006-05-04 | 2012-07-31 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US10301313B2 (en) | 2006-05-04 | 2019-05-28 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9266888B2 (en) | 2006-05-04 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Polymorphs |
US20110065731A1 (en) * | 2006-05-04 | 2011-03-17 | Boehringer Ingelheim International Gmbh | Uses of dpp-iv inhibitors |
US20070259900A1 (en) * | 2006-05-04 | 2007-11-08 | Peter Sieger | Polymorphs |
US20070281940A1 (en) * | 2006-05-04 | 2007-12-06 | Klaus Dugi | Uses of dpp-iv inhibitors |
US20080107731A1 (en) * | 2006-05-04 | 2008-05-08 | Anja Kohlrausch | Dpp iv inhibitor formulations |
US9493462B2 (en) | 2006-05-04 | 2016-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
US10080754B2 (en) | 2006-05-04 | 2018-09-25 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US9815837B2 (en) | 2006-05-04 | 2017-11-14 | Boehringer Ingelheim International Gmbh | Polymorphs |
US8071583B2 (en) | 2006-08-08 | 2011-12-06 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus |
US20110112069A1 (en) * | 2007-08-17 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
US20090110647A1 (en) * | 2007-10-24 | 2009-04-30 | Peter Richardson | Method of preventing adverse effects by glp-1 |
US8377869B2 (en) | 2007-10-24 | 2013-02-19 | Mannkind Corporation | Method of preventing adverse effects by GLP-1 |
US10022379B2 (en) | 2008-04-03 | 2018-07-17 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US20110206766A1 (en) * | 2008-04-03 | 2011-08-25 | Boehringer Ingelheim International Gmbh | Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9415016B2 (en) | 2008-04-03 | 2016-08-16 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9155705B2 (en) | 2008-04-03 | 2015-10-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US10973827B2 (en) | 2008-04-03 | 2021-04-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US20110092510A1 (en) * | 2008-06-03 | 2011-04-21 | Boehringer Ingelheim International Gmbh | Dpp-iv inhibitors for use in the treatment of nafld |
US9446133B2 (en) | 2008-06-13 | 2016-09-20 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9339615B2 (en) | 2008-06-13 | 2016-05-17 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9192675B2 (en) | 2008-06-13 | 2015-11-24 | Mankind Corporation | Dry powder inhaler and system for drug delivery |
US9511198B2 (en) | 2008-06-13 | 2016-12-06 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10201672B2 (en) | 2008-06-13 | 2019-02-12 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
US10751488B2 (en) | 2008-06-13 | 2020-08-25 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10675421B2 (en) | 2008-06-20 | 2020-06-09 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US8853156B2 (en) | 2008-08-06 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US10034877B2 (en) | 2008-08-06 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US9486526B2 (en) | 2008-08-06 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
US20110190322A1 (en) * | 2008-08-14 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
US9212183B2 (en) | 2008-12-23 | 2015-12-15 | Boehringer Ingelheim International Gmbh | Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
US9655850B2 (en) | 2008-12-29 | 2017-05-23 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US10172850B2 (en) | 2008-12-29 | 2019-01-08 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
WO2010079197A1 (en) * | 2009-01-07 | 2010-07-15 | Boehringer Ingelheim International Gmbh | Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor |
US8846695B2 (en) | 2009-01-07 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
WO2010080964A1 (en) * | 2009-01-08 | 2010-07-15 | Mannkind Corporation | Method for treating hyperglycemia with glp-1 |
EP2853268A1 (en) * | 2009-01-08 | 2015-04-01 | Mannkind Corporation | Treatment of hyperglycemia with GLP-1 |
US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
US10092571B2 (en) | 2009-11-27 | 2018-10-09 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
US10004747B2 (en) | 2010-05-05 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9603851B2 (en) | 2010-05-05 | 2017-03-28 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9149478B2 (en) | 2010-06-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US10130709B2 (en) | 2011-06-17 | 2018-11-20 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US8962636B2 (en) | 2011-07-15 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9199998B2 (en) | 2011-07-15 | 2015-12-01 | Boehringer Ingelheim Internatioal Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9610351B2 (en) | 2011-10-24 | 2017-04-04 | Mannkind Corporation | Methods and compositions for treating pain |
US10258664B2 (en) | 2011-10-24 | 2019-04-16 | Mannkind Corporation | Methods and compositions for treating pain |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US10195203B2 (en) | 2012-05-14 | 2019-02-05 | Boehringr Ingelheim International GmbH | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9713618B2 (en) | 2012-05-24 | 2017-07-25 | Boehringer Ingelheim International Gmbh | Method for modifying food intake and regulating food preference with a DPP-4 inhibitor |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US10772865B2 (en) | 2015-03-09 | 2020-09-15 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11400072B2 (en) | 2015-03-09 | 2022-08-02 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Also Published As
Publication number | Publication date |
---|---|
MXPA02012272A (es) | 2003-04-25 |
WO2002002560A2 (en) | 2002-01-10 |
PL360856A1 (en) | 2004-09-20 |
US20040034014A1 (en) | 2004-02-19 |
WO2002002560A3 (en) | 2002-04-25 |
EP1301187A2 (en) | 2003-04-16 |
US7235538B2 (en) | 2007-06-26 |
HUP0301622A3 (en) | 2006-05-29 |
JP2004502690A (ja) | 2004-01-29 |
HUP0301622A2 (hu) | 2003-09-29 |
AU2001268958B2 (en) | 2006-03-09 |
AU6895801A (en) | 2002-01-14 |
EP1301187B1 (en) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1301187B1 (en) | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) | |
AU2001268958A1 (en) | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv | |
US7192952B2 (en) | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | |
US20030199528A1 (en) | Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV | |
EP1404675B1 (en) | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes | |
EP1496877B1 (en) | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | |
WO2004033455A2 (en) | Hemisuccinate salts of heterocyclic dpp-iv inhibitors | |
US7074798B2 (en) | Xanthine derivative and DPPIV inhibitor | |
KR101446692B1 (ko) | 1-[(3-시아노-피리딘-2-일)메틸]-3-메틸-7-(2-부틴-1-일)-8-(3-아미노-피페리딘-1-일)-크산틴의 하이드로클로라이드 및 수화물, 이의 제조법 및 의약으로서의 이의 용도 | |
US7906539B2 (en) | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions | |
US6977300B2 (en) | A2B adenosine receptor antagonists | |
JP2008513390A (ja) | 新規3−メチル−7−ブチニル−キサンチン、その製造方法及び医薬組成物としての使用 | |
US20070197552A1 (en) | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | |
JP2007531780A (ja) | 新規な2−アミノ−イミダゾ[4,5−d]ピリダジン−4−オン及び2−アミノ−イミダゾ[4,5−c]ピリダジン−4−オン、その製法及び医薬としての使用 | |
US6187780B1 (en) | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity | |
EP0559893A1 (en) | Xanthine derivative | |
EP1561752A1 (en) | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NOVO NORDISK A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KANSTRUP, ANDERS BENDTZ;CHRISTIANSEN, LISE BROWN;LUNDBECK, JANE MARIE;AND OTHERS;REEL/FRAME:012279/0575;SIGNING DATES FROM 20010913 TO 20010920 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |